Report Sections

See All Reports

  • HP:0002088: Abnormal lung morphology
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002088: Abnormal lung morphology

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO


    Correlated Drug Terms (49)


    Name (Synonyms) Correlation
    drug1841 Low dose prednisolone Wiki 0.22
    drug3180 Sterile Normal Saline for Intravenous Use Wiki 0.22
    drug3710 bovhyaluronidase azoxymer Wiki 0.22
    Name (Synonyms) Correlation
    drug1954 Medium dose prednisolone Wiki 0.22
    drug710 Centricyte 1000 Wiki 0.22
    drug2914 SELF-BREATHE Wiki 0.22
    drug2653 Pulmonary function tests Wiki 0.22
    drug2778 Rehabilitation-focused program Wiki 0.22
    drug1883 MLS Laser Wiki 0.22
    drug2000 Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF) Wiki 0.22
    drug1642 Interferon-Alpha2B Wiki 0.22
    drug3274 Tele-Pulmonary rehabilitation Wiki 0.22
    drug2150 Nintedanib Wiki 0.22
    drug1583 Imaging Wiki 0.22
    drug875 Convalescent Serum Wiki 0.22
    drug953 DWJ1248 Wiki 0.22
    drug1378 HCFWO Wiki 0.22
    drug326 Awake Prone Positioning Wiki 0.22
    drug697 Carotid Artery Reactivity Testing Wiki 0.22
    drug2773 Regular Inpatient Medical Care Wiki 0.22
    drug3024 Serology for Covid-19 Wiki 0.22
    drug3824 imaging, blood tests Wiki 0.22
    drug1518 Hydroxychloroquine, Clindamycin, Primaquine - high dose. Wiki 0.22
    drug1562 IV Deployment Of cSVF In Sterile Normal Saline IV Solution Wiki 0.22
    drug2091 NP-120 (Ifenprodil) Wiki 0.22
    drug1517 Hydroxychloroquine, Clindamycin Wiki 0.22
    drug2144 Nicotinamide riboside Wiki 0.22
    drug1516 Hydroxychloroquine, Azithromycin Wiki 0.22
    drug3117 Standard Care Plus Monitoring Wiki 0.22
    drug2654 Pulmonary tele-rehabilitation Wiki 0.22
    drug1519 Hydroxychloroquine, Clindamycin, Primaquine - low dose. Wiki 0.22
    drug1113 EarSats Pulse Oximeter Probe Wiki 0.22
    drug1780 Liberase Enzyme (Roche) Wiki 0.22
    drug380 BRII-196 Wiki 0.22
    drug567 COVI-AMG Wiki 0.22
    drug1520 Hydroxychloroquine, Doxycycline Wiki 0.22
    drug665 CYNK-001 Wiki 0.22
    drug217 Angiography scanner Wiki 0.22
    drug3738 conjunctival swab Wiki 0.15
    drug4037 survey Wiki 0.15
    drug1869 Lung ultrasound Wiki 0.09
    drug2951 Saliva collection Wiki 0.09
    drug481 Blood sampling Wiki 0.08
    drug3132 Standard care Wiki 0.07
    drug1824 Losartan Wiki 0.07
    drug1995 Methylprednisolone Wiki 0.06
    drug2448 Placebo Wiki 0.05
    drug2782 Remdesivir Wiki 0.04
    drug3375 Tocilizumab Wiki 0.04

    Correlated MeSH Terms (39)


    Name (Synonyms) Correlation
    D008171 Lung Diseases, NIH 0.98
    D017563 Lung Diseases, Interstitial NIH 0.35
    D001987 Bronchiectasis NIH 0.25
    Name (Synonyms) Correlation
    D008173 Lung Diseases, Obstructive NIH 0.25
    D011658 Pulmonary Fibrosis NIH 0.23
    D001469 Barotrauma NIH 0.22
    D011649 Pulmonary Alveolar Proteinosis NIH 0.22
    D004646 Emphysema NIH 0.22
    D017093 Liver Failure NIH 0.22
    D018410 Pneumonia, Bacterial NIH 0.22
    D030341 Nidovirales Infections NIH 0.15
    D054990 Idiopathic Pulmonary Fibrosis NIH 0.15
    D011024 Pneumonia, Viral NIH 0.14
    D005355 Fibrosis NIH 0.13
    D003550 Cystic Fibrosis NIH 0.13
    D000755 Anemia, Sickle Cell NIH 0.11
    D007154 Immune System Diseases NIH 0.10
    D003333 Coronaviridae Infections NIH 0.10
    D029424 Pulmonary Disease, Chronic Obstructive NIH 0.09
    D012140 Respiratory Tract Diseases NIH 0.09
    D011665 Pulmonary Valve Insufficiency NIH 0.08
    D006331 Heart Diseases NIH 0.08
    D012327 RNA Virus Infections NIH 0.08
    D004417 Dyspnea NIH 0.07
    D011014 Pneumonia NIH 0.06
    D011655 Pulmonary Embolism NIH 0.06
    D004617 Embolism NIH 0.05
    D012120 Respiration Disorders NIH 0.05
    D045169 Severe Acute Respiratory Syndrome NIH 0.05
    D007249 Inflammation NIH 0.04
    D018352 Coronavirus Infections NIH 0.04
    D002318 Cardiovascular Diseases NIH 0.04
    D012141 Respiratory Tract Infections NIH 0.04
    D003141 Communicable Diseases NIH 0.03
    D014777 Virus Diseases NIH 0.02
    D013577 Syndrome NIH 0.02
    D007239 Infection NIH 0.02
    D012127 Respiratory Distress Syndrome, Newborn NIH 0.02
    D012128 Respiratory Distress Syndrome, Adult NIH 0.02

    Correlated HPO Terms (13)


    Name (Synonyms) Correlation
    HP:0006515 Interstitial pneumonitis HPO 0.35
    HP:0002110 Bronchiectasis HPO 0.25
    HP:0006536 Pulmonary obstruction HPO 0.25
    Name (Synonyms) Correlation
    HP:0002206 Pulmonary fibrosis HPO 0.23
    HP:0006517 Intraalveolar phospholipid accumulation HPO 0.22
    HP:0001399 Hepatic failure HPO 0.22
    HP:0006510 Chronic pulmonary obstruction HPO 0.09
    HP:0010444 Pulmonary insufficiency HPO 0.08
    HP:0002098 Respiratory distress HPO 0.07
    HP:0002090 Pneumonia HPO 0.06
    HP:0002204 Pulmonary embolism HPO 0.06
    HP:0011947 Respiratory tract infection HPO 0.04
    HP:0001626 Abnormality of the cardiovascular system HPO 0.04

    Clinical Trials

    Navigate: Correlations   HPO

    There are 21 clinical trials


    1 Time of Recovery and Prognostic Factors of COVID-19 Pneumonia

    It has been reported that nearly half of the patients who are hospitalized for Covid-19 pneumonia have on admission old age or comorbidities. In particular, hypertension was present in 30% of the cases, diabetes in 19%, coronary heart disease in 8% and chronic obstructive lung disease in 3% of the patients. Amazingly, in the two major studies published in the Lancet (Zhou F et al Lancet 2020) and in the New England Journal of Medicine (Guan W et al 2020), the weight of the subjects as well their body mass index (BMI) were omitted. However, obesity, alone or in association with diabetes, can be a major predisposition factor for Covid-19 infection. The primary end-point of our prospective, observational study is to assess the recovery rate in patients with diagnosis of Covid-19 pneumonia. Among the other secondary end-points, we intend to find the predictors of the time to clinical improvement or hospital discharge in patients affected by Covid-19 pneumonia.

    NCT04324684
    Conditions
    1. Pneumonia, Viral
    2. Hypertension
    3. Diabetes Mellitus
    4. Obesity
    5. Cardiovascular Diseases
    6. Obstructive Lung Disease
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases Lung Diseases, Obstructive Cardiovascular Diseases
    HPO:Abnormal lung morphology Abnormality of the cardiovascular system Pneumonia Pulmonary obstruction

    Primary Outcomes

    Description: mean rate of recovery in patients with diagnosis of Covid-19 pneumonia, who present with complications at the time of hospital admission (such as diabetes, obesity, cardiovascular disease, hypertension or respiratory failure), with the mean recovery rate in patients without any of the above-mentioned complications.

    Measure: rate of recovery

    Time: 3 weeks

    Secondary Outcomes

    Description: comparison of the survival curves (times to improvement) in the two groups (patients with and without complications) and among patients presenting with different types of complications

    Measure: time to improvement

    Time: 3 weeks

    Description: the efficacy of different pharmaceutical treatment against Covid-19

    Measure: efficacy of treatments

    Time: 3 weeks

    Description: liver, kidney or multiorgan failure, cardiac failure

    Measure: organ failure

    Time: 3 weeks
    2 Use of cSVF For Residual Lung Damage (COPD/Fibrotic Lung Disease After Symptomatic COVID-19 Infection For Residual Pulmonary Injury or Post-Adult Respiratory Distress Syndrome Following Viral (SARS-Co-2) Infection

    COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality. A short review includes: - Early December, 2019 - A pneumonia of unknown cause was detected in Wuhan, China, and was reported to the World Health Organization (WHO) Country Office. - January 30th, 2020 - The outbreak was declared a Public Health Emergency of International Concern. - February 7th, 2020 - 34-year-old Ophthalmologist who first identified a SARS-like coronavirus) dies from the same virus. - February 11th, 2020 - WHO announces a name for the new coronavirus disease: COVID-19. - February 19th, 2020 - The U.S. has its first outbreak in a Seattle nursing home which were complicated with loss of lives.. - March 11th, 2020 - WHO declares the virus a pandemic and in less than three months, from the time when this virus was first detected, the virus has spread across the entire planet with cases identified in every country including Greenland. - March 21st, 2020 - Emerging Infectious Disease estimates the risk for death in Wuhan reached values as high as 12% in the epicenter of the epidemic and ≈1% in other, more mildly affected areas. The elevated death risk estimates are probably associated with a breakdown of the healthcare system, indicating that enhanced public health interventions, including social distancing and movement restrictions, should be implemented to bring the COVID-19 epidemic under control." March 21st 2020 -Much of the United States is currently under some form of self- or mandatory quarantine as testing abilities ramp up.. March 24th, 2020 - Hot spots are evolving and identified, particularly in the areas of New York-New Jersey, Washington, and California. Immediate attention is turned to testing, diagnosis, epidemiological containment, clinical trials for drug testing started, and work on a long-term vaccine started. The recovering patients are presenting with mild to severe lung impairment as a result of the viral attack on the alveolar and lung tissues. Clinically significant impairment of pulmonary function appears to be a permanent finding as a direct result of the interstitial lung damage and inflammatory changes that accompanied. This Phase 0, first-in-kind for humans, is use of autologous, cellular stromal vascular fraction (cSVF) deployed intravenously to examine the anti-inflammatory and structural potential to improve the residual, permanent damaged alveolar tissues of the lungs.

    NCT04326036
    Conditions
    1. Pulmonary Alveolar Proteinosis
    2. COPD
    3. Idiopathic Pulmonary Fibrosis
    4. Viral Pneumonia
    5. Coronavirus Infection
    6. Interstitial Lung Disease
    Interventions
    1. Procedure: Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF)
    2. Device: Centricyte 1000
    3. Procedure: IV Deployment Of cSVF In Sterile Normal Saline IV Solution
    4. Drug: Liberase Enzyme (Roche)
    5. Drug: Sterile Normal Saline for Intravenous Use
    MeSH:Infection Communicable Diseases Coron Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Lung Diseases Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Lung Diseases, Interstitial Pulmonary Alveolar Proteinosis
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Intraalveolar phospholipid accumulation Pulmonary fibrosis

    Primary Outcomes

    Description: Reporting of Adverse Events or Severe Adverse Events Assessed by CTCAE v4.0

    Measure: Incidence of Treatment-Emergent Adverse Events

    Time: 1 month

    Secondary Outcomes

    Description: High Resolution Computerized Tomography of Lung (HRCT Lung) for Fluidda Analysis comparative at baseline and 3 and 6 months post-treatment comparative analytics

    Measure: Pulmonary Function Analysis

    Time: baseline, 3 Month, 6 months

    Description: Finger Pulse Oximetry taken before and after 6 minute walk on level ground, compare desaturation tendency

    Measure: Digital Oximetry

    Time: 3 months, 6 months
    3 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Diagnostic Targets for Customized Medicine.

    The patients enrolled in this study will be all patients entering triage with suspicion of SARS-CoV2. Planned activities are required by the nasopharyngeal swab in parallel with the analysis of the conjunctival swab to identify new potential alternative and equally effective diagnostic pathways. Simultaneously systemic data (as Pulmonary images, hematological parameters etc.) will be collected to observe a possible correlation between conjunctival swab positivity and systemic impairment.

    NCT04364594
    Conditions
    1. COVID 19
    2. Pulmonary Disease
    Interventions
    1. Diagnostic Test: conjunctival swab
    MeSH:Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: Collection of conjunctival cell samples from eyes of COVID-19 patients. Analysis of conjunctival cells by real-time PCR to document presence of COVID-19. Binary outcome: yes, no. To evaluate the result in relation to nasopharyngeal swab (binary outcome yes, no) and to correlate conjunctival with nasopharyngeal swab positivity

    Measure: Conjunctival swab results based on RT-PCR

    Time: 2 months

    Secondary Outcomes

    Description: To evaluate the agreement between conjunctival swab positivity and the degree of systemic impairment. The latter will be measured on the basis of pulmonary disease severity as assessed by a standardized scale (Occhipinti et al 2019) for interstitial lung involvement in systemic sclerosis; the blood measurements of d-dimer, LDH and reactive CP.

    Measure: Conjunctival swab positivity in relation to Pulmonary and blood abnormalities

    Time: 2 months
    4 A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19

    This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.

    NCT04365101
    Conditions
    1. Coronavirus
    2. Coronavirus Infection
    3. Severe Acute Respiratory Syndrome Coronavirus 2
    4. Pneumonia
    5. Pneumonia, Viral
    6. Lung Diseases
    7. Respiratory Tract Disease
    8. Respiratory Tract Infections
    9. Coronaviridae Infections
    10. Nidovirales Infections
    11. RNA Virus Infections
    12. Virus Disease
    13. Immunologic Disease
    14. ARDS
    15. Immunologic Factors
    16. Physiological Effects of Drugs
    17. Antiviral Agents
    18. Anti-infective Agents
    19. Analgesics
    20. Antimetabolites, Antineoplastic
    Interventions
    1. Biological: CYNK-001
    MeSH:Infection Communicable Diseases Respiratory Tract Infections Virus Diseases Coronavirus I Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral RNA Virus Infections Coronaviridae Infections Nidovirales Infections Pneumonia Lung Diseases Respiratory Tract Diseases Immune System Diseases
    HPO:Abnormal lung morphology Pneumonia Respiratory tract infection

    Primary Outcomes

    Description: Number and severity of adverse events

    Measure: Phase 1: Frequency and Severity of Adverse Events (AE)

    Time: Up to 6 months

    Description: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR

    Measure: Phase 1: Rate of clearance of SARS-CoV-2

    Time: Up to 6 months

    Description: Proportion of subjects who improved clinical symptoms related to lower respiratory tract infection, as measured by National Early Warning Score 2 (NEWS2) score.

    Measure: Phase 1: Rate of clinical improvement

    Time: Up to 6 months

    Description: Time from the date of randomization to the clearance of SARS-CoV-2 by rRT-PCR. Negative results will need to be confirmed by a second negative result in the same sample type at least 24 hours after the first negative result.

    Measure: Phase 2: Time to Clearance of SARS-CoV-2

    Time: Up to 28 days

    Description: Time from the date of randomization to the first date of improved clinical symptoms related to lower respiratory tract infection. Improvement as measured by National Early Warning Score 2 (NEWS2) Score.

    Measure: Phase 2: Time to Clinical Improvement by NEWS2 Score

    Time: Up to 28 days

    Secondary Outcomes

    Description: Proportion of subjects with "negative" measurement of COVID-19 by rRT-PCR

    Measure: Rate of Clearance of SARS-CoV-2

    Time: Up to 6 months

    Description: Number and severity of adverse events

    Measure: Phase 2: Frequency and Severity of Adverse Events (AE)

    Time: up to 6 months

    Description: Time to medical discharge as an assessment of overall clinical benefit

    Measure: Overall Clinical Benefit by time to medical discharge

    Time: up to 6 months

    Description: Hospital utilization will be measured as an assessment of overall clinical benefit

    Measure: Overall Clinical Benefit by hospital utilization

    Time: up to 6 months

    Description: Mortality rate will be measured as an assessment of overall clinical benefit

    Measure: Overall Clinical Benefit by measuring mortality rate

    Time: up to 6 months

    Description: Assess the impact of CYNK-001 on changes in sequential organ failure assessment (SOFA) score.

    Measure: Impact of CYNK-001 on sequential organ failure assessment (SOFA) score

    Time: Up to 28 days

    Description: Time from randomization to the date of disappearance of virus from lower respiratory tract infection (LRTI) specimen where it has previously been found (induced sputum, endotracheal aspirate).

    Measure: Time to Pulmonary Clearance

    Time: Up to 28 days

    Description: For ventilatory support subjects, the days with supplemental oxygen-free.

    Measure: Supplemental oxygen-free days

    Time: Up to 28 days

    Description: Proportion of subjects who need invasive or non-invasive ventilation

    Measure: Proportion of subjects requiring ventilation

    Time: Up to 28 days
    5 Major Determinants of COVID-19 Associated Pneumonia

    Molecular testing (e.g PCR) of respiratory tract samples is the recommended method for the identification and laboratory confirmation of COVID-19 cases. Recent evidence reported that the diagnostic accuracy of many of the available RT-PCR tests for detecting SARS-CoV2 may be lower than optimal. Of course, the economical and clinical implications of diagnostic errors are of foremost significance and in case of infectious outbreaks, namely pandemics, the repercussions are amplified. False positives and false-negative results may jeopardize the health of a single patient and may affect the efficacy of containment of the outbreak and of public health policies. In particular, false-negative results contribute to the ongoing of the infection causing further spread of the virus within the community, masking also other potentially infected people.

    NCT04387799
    Conditions
    1. Pneumonia, Viral
    2. Pneumonia, Bacterial
    3. Coronavirus Infection
    4. Obstructive Lung Disease
    Interventions
    1. Diagnostic Test: Serology for Covid-19
    MeSH:Pneumonia, Bacterial Coronavirus Infections Severe Acute Respiratory Syndrome Pneumonia, Viral Pneumonia Lung Diseases Lung Diseases, Obstructive
    HPO:Abnormal lung morphology Pneumonia Pulmonary obstruction

    Primary Outcomes

    Description: assess if inpatients who presented with pneumonia but had a negative test for Covid-19 are positive at the serology for SARS-CoV-2.

    Measure: Serology

    Time: 3 weeks

    Secondary Outcomes

    Description: to find if the combination of CT scan and serology could help us in the identification of those patients who were initially negative at laboratory testing alone.

    Measure: Efficacy of CT scan and Serology

    Time: 3 weeks

    Description: the efficacy of different pharmaceutical treatments against Covid-19

    Measure: Efficacy of different pharmaceutical treatments

    Time: 3 weeks
    6 Multiwave Locked System (MLS) Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease

    The aim of this study is to evaluate the effectiveness of MLS laser therapy as a treatment for pulmonary complications due to COVID-19 infection.

    NCT04391712
    Conditions
    1. COVID-19
    Interventions
    1. Device: MLS Laser
    2. Other: Regular Inpatient Medical Care
    MeSH:Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: ICU on vent, ICU not requiring ventilation, Discharge to Rehab requiring assistance, Discharge to Home unable to perform ADL's, Discharge to Home able to perform ADL's

    Measure: Patient Disposition Post treatment

    Time: 7 days

    Description: Patients oxygen requirements pulse oximetry will be evaluated for change from pre and post individual treatment as well as end of protocol

    Measure: oxygenation

    Time: Daily for 4 days

    Description: The change in pre treatment levels and 24 hours post final treatment

    Measure: IL-6 levels

    Time: First four days of trial

    Description: Pre treatment CXR will be compared to post treatment CXR using the RALE CXR evaluation scale

    Measure: Chest Xray radiographic results

    Time: 7 Days

    Description: The change in pretreatment and post treatment BCRSS will be evaluated

    Measure: Brescia-COVID Respiratory Severity Scale

    Time: 7 days

    Description: The change in pretreatment and post treatment scores will be evaluated

    Measure: SMART-COP Score

    Time: 7 days

    Description: The change in pretreatment and post treatment scores will be evaluated

    Measure: PSI Score

    Time: 7 days

    Description: The change in pretreatment and post treatment levels will be evaluated The change in pretreatment and post treatment levels will be evalutated

    Measure: CRP levels

    Time: 7 days
    7 Randomized-controlled Trial of HFNC Alone vs HFNC and Awake Self-proning for Treatment of Severe COVID-19

    Prone positioning is an established intervention in mechanically ventilated acute respiratory distress syndrome (ARDS) patients, with demonstrated reductions in mortality. Preliminary data suggest that awake proning in patients with COVID-19 treated with high-flow nasal oxygenation (HFNO) improves gas exchanges, and might be associated with a reduced need of mechanical ventilation, and reduced mortality. Further investigation in a formal randomized-controlled trial is need.

    NCT04395144
    Conditions
    1. Coronavirus Infection
    2. COVID
    3. Severe Acute Respiratory Syndrome
    4. Respiratory Failure
    5. Respiratory Insufficiency
    6. Respiratory Distress Syndrome
    7. ARDS
    8. Lung Diseases
    Interventions
    1. Procedure: Awake Prone Positioning
    2. Procedure: Standard care
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Lung Diseases Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Respiratory Insufficiency Pulmonary Valve Insufficiency Syndrome
    HPO:Abnormal lung morphology Pulmonary insufficiency

    Primary Outcomes

    Measure: Rate of Therapeutic failure, defined as a combined outcome of rate of intubation or death

    Time: Up to 28 days after randomization

    Secondary Outcomes

    Measure: Intubation rate

    Time: Up to 28 days after randomization

    Measure: Mortality

    Time: Up to 28 days after randomization

    Measure: Days spent on mechanical ventilation

    Time: Until discharge, up to 24 weeks after randomization

    Measure: Days spent in the ICU

    Time: Until discharge, up to 24 weeks after randomization

    Measure: Hospital stay (in days)

    Time: From admission to discharge, up to 24 weeks after randomization

    Other Outcomes

    Description: Total time spent in prone position, as recorded by nursing or respiratory therapists

    Measure: Time in prone position

    Time: Up to 28 days post randomization

    Description: Daily evolution of oxygenation

    Measure: Oxygenation (SpO2/FiO2 ratio)

    Time: Until HFNC weaning, or up to 14 days after randomization, whichever is first
    8 Development of Interstitial Lung Disease (ILD) in Patients With Severe SARS-CoV-2 Infection

    COVID-19, the infectious disease caused by the novel coronavirus SARS-CoV-2, currently poses a global economic, social, political and medical challenge. The virus originated in December 2019 in Wuhan, China, and has spread rapidly around the world. Currently, European countries, including Austria, are severely affected.The most common computed tomographic changes in acute lung injury include bilateral and subpleural milk glass opacity, consolidation in lower lobes, or both. In the intermediate phase of the infection (4-14 days after the onset of symptoms) a so-called "crazy paving" may occur. The most prominent radiological changes occur around day 10, followed by gradual resolution, which begins two weeks after the onset of symptoms. Given the phylogenetic relationship between SARS-CoV-1 and SARS-CoV-2, the similar clinical course in severe cases and overlapping CT patterns in the acute setting, persistent radiological and pulmonary functional changes in survivors are conceivable. It is also conceivable that a proportion of survivors will develop progressive ILD, either due to viral or ventilator-induced alveolar damage, or both. Here, the investigators intend to investigate COVID-19 survivors through clinical examinations, functional lung examinations, HR-CT scans, and by determining the "immunofibrotic" pattern in peripheral mononuclear cells (PBMCs) 1, 3, and 6 months after discharge.

    NCT04416100
    Conditions
    1. Covid-19
    2. Pulmonary Fibrosis
    Interventions
    1. Diagnostic Test: Pulmonary function tests
    2. Diagnostic Test: Imaging
    3. Biological: Blood sampling
    MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

    Primary Outcomes

    Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 1 month after discharge or diagnosis of COVID-19 disease by the use of HR-CT.

    Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 1 month

    Time: 1 month

    Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 3 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT

    Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 3 months

    Time: 3 months

    Description: Define the frequency of ILD and pulmonary vascular disease in SARS-CoV-2 infected patients with a severe/prolonged Course (inhospital stay, either on the normal ward or ICU), with and without oxygen supplementation, non-invasive or invasive ventilation) at 6 months after discharge or diagnosis of COVID-19 disease by the use of HR-CT

    Measure: Pattern of pulmonary abnormalities in SARS-CoV2 infected patients after 6 months

    Time: 6 months
    9 SequelaeCov: a Prospective Study on Lung Damage Caused by SARS-CoV-2 Pneumonia

    Pneumonia is a recurrent element of COVID-19 infection, it is often associated with development of respiratory failure and patients frequently need various degrees of oxygen therapy up to non invasive ventilation (NIV-CPAP) and invasive mechanical ventilation (IMV). Main purpose of this study is to evaluate with non invasive clinical instruments (pletysmography, Diffusion lung capacity for carbon monoxide -DLCO-, six minute walking test and dyspnea scores) and radiological tools (chest X-ray and chest CT scan) the development of medium-to-long term pulmonary sequelae caused by SARS-CoV-2 pneumonia.

    NCT04435327
    Conditions
    1. COVID
    2. Pneumonia, Viral
    3. Barotrauma
    4. Interstitial Lung Disease
    5. Bronchiectasis Adult
    6. Emphysema
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases Bronchiectasis Lung Diseases, Interstitial Emphysema Barotrauma
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Interstitial pneumonitis Pneumonia

    Primary Outcomes

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T1 at 6 months from discharge

    Description: Reduction below 80% of predicted values of DLCO

    Measure: Reduction of Diffusion of Lung CO (DLCO, single breath technique)

    Time: T2 at 12 months from discharge

    Secondary Outcomes

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in maximum distance walked

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T1 at 6 months from discharge

    Description: reduction in oxygen saturation nadir

    Measure: Alterations in 6 minute walking test (6MWT)

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Vital Capacity (FVC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Vital Capacity (VC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Forced Expiratory Volume in the 1st second (FEV1, L%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: reduction of Total Lung Capacity (TLC, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of Total Lung Capacity (TLC, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV,%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Residual Volume (RV, L)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Residual Volume (RV, %)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (absolute value)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: increase of Specific Airway Resistance (sRAW) (%)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Motley Index (VR/CPT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T1 at 6 months from discharge

    Description: alterations of Tiffeneau Index (IT)

    Measure: Alterations of pletismography

    Time: T2 at 12 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: reduction of PaO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T1 at 6 months from discharge

    Description: alteration of PaCO2 mmHg

    Measure: Alterations of Arterial Blood Gas Analysis

    Time: T2 at 12 months from discharge

    Description: Modified Medical Research Council - mMRC > 0 (minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T1 at 6 months from discharge

    Description: Modified Medical Research Council - mMRC > 0(minimum 0, maximum 4; higher score means worse outcome)

    Measure: Abnormal Dyspnea Score

    Time: T2 at 12 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T1 at 6 months from discharge

    Description: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Measure: Presence and extension of abnormal pulmonary lung sounds at auscultation

    Time: T2 at 12 months from discharge

    Description: Presence and extension of radiological alterations at chest X-ray

    Measure: Presence and extension of radiological alterations at chest X-ray

    Time: T1 at 6 months from discharge

    Description: Presence and extension of radiological alterations at chest CT scan

    Measure: Presence and extension of radiological alterations at chest CT scan

    Time: T2 at 12 months from discharge
    10 Long-term Sequelae of Severe Sars-CoV-2 Infections

    By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally, having a tremendous impact on global health and economy. To date, no vaccine or therapy is available. Severe courses of the infection not only affect the lungs, but also other organs like the heart, kidney, or liver. The lack of preexisting immunity might at least partially explain the affection of extra pulmonary organs not yet seen in infections due to other respiratory viruses. In this observational investigation the study group will follow up on patients that have been hospitalized due to a SARS-CoV-2 infection, and monitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system. Our that in some patients, organ damage will persist and require long-term medical care.

    NCT04442789
    Conditions
    1. Lung Diseases
    2. Cardiac Disease
    3. Inflammatory Reaction
    MeSH:Lung Diseases Heart Diseases Inflammation
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: Identify organ dysfunction after SARS-CoV-2 infections

    Measure: Sequelae after COVID-19

    Time: 12 months, extension if required
    11 Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With SARS Coronavirus (COV-2) Lung Disease

    The current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is complicated by pneumonia (15 to 20% of cases) requiring hospitalization with oxygen therapy. Almost 20 to 25% of hospitalized patients require intensive care and resuscitation; half die. The main cause of death is acute respiratory distress syndrome (ARDS). However, some deaths have been linked to pulmonary embolism (PE). Recognition of PE is important because there is specific treatment to limit its own mortality. The identification of biological parameters of hemostasis predictive of thromboembolic disease is crucial in these patients. To evaluate the frequency of PE in the patients having to be hospitalized is to practice of a systematic thoracic angiography scanner in the patients having no contra-indication for its realization, as well as during hospitalization in patients deteriorating without any other obvious cause. The thromboembolic events and disturbances of the coagulation system described in patients with SARS-CoV-2 pneumonitis suggest that this viral infection is associated with an increase in the activation of coagulation contributing to the occurrence of thrombosis and especially from PE.

    NCT04479540
    Conditions
    1. Pneumonia, Viral
    Interventions
    1. Radiation: Angiography scanner
    MeSH:Pneumonia, Viral Pneumonia Lung Diseases Pulmonary Embolism Embolism
    HPO:Abnormal lung morphology Pneumonia Pulmonary embolism

    Primary Outcomes

    Description: Rate of patients with pulmonary embolism diagnosed by thoracic angiography scanner

    Measure: Rate of patients with pulmonary embolism

    Time: up to Day 12

    Secondary Outcomes

    Description: Measure of prothrombin level to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: Prothrombin level measurement

    Time: up to Day 12

    Description: Measure of activated partial thromboplastin time to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: activated partial thromboplastin time measurement

    Time: up to Day 12

    Description: Measure of fibrinogen to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: Fibrinogen measurement

    Time: up to Day 12

    Description: Measure of D-dimers to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: D-dimers measurement

    Time: up to Day 12

    Description: Measure of Protein C to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: Protein C measurement

    Time: up to Day 12

    Description: Measure of Willebrand antigen to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: Willebrand antigen measurement

    Time: up to Day 12

    Description: Measure of Soluble tissue factor to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: Soluble tissue factor measurement

    Time: up to Day 12

    Description: Measure of soluble thrombomodulin to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: Soluble thrombomodulin measurement

    Time: up to Day 12

    Description: Measure of E-selectin to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: E-selectin measurement

    Time: up to Day 12

    Description: Measure of thrombin-antithrombin complex to assess hemostasis parameters of patients with SARS-COV-2pneumonitis during hospitalization

    Measure: Thrombin-antithrombin complex measurement

    Time: up to Day 12

    Description: Assessment of clot formation curve by Thrombodynamics® to identify ones predictive of the onset of Pulmonary Embolism or a poor prognosis

    Measure: Assessment of clot formation curve

    Time: Day 1

    Description: Assessment of thrombin generation by Thrombodynamics® to identify ones predictive of the onset of Pulmonary Embolism or a poor prognosis

    Measure: Assessment of thrombin generation

    Time: Day 1

    Description: Assessment of fibrinolysis by Thrombodynamics® to identify ones predictive of the onset of Pulmonary Embolism or a poor prognosis

    Measure: Assessment of fibrinolysis

    Time: Day 1

    Description: Determine patient mortality

    Measure: Mortality

    Time: Day 30
    12 A Feasibility, Randomised Controlled Trial of Tele-rehabilitation Following COVID-19

    Since initial reports of a novel coronavirus emerged from Hubei province, China, the world has been engulfed by a pandemic with over 3 million cases and 225,000 deaths by 30th April 2020. Health care systems around the world have struggled to cope with the number of patients presenting with COVID-19 (the disease caused by the SARS-CoV-2 virus). Although the majority of people infected with the virus have a mild disease, around 20% experience a more severe illness leading to hospital admission and sometimes require treatment in intensive care. People that survive severe COVID-19 are likely to have persistent health problems that would benefit from rehabilitation. Pulmonary rehabilitation (PR) is a multidisciplinary program which is designed to improve physical and social performance and is typically provided for people with chronic lung conditions. PR courses typically last 6-12 weeks with patients attending classes once or twice weekly and consist of exercise and education components. PR is known to improve symptoms (e.g. breathlessness), quality of life and ability to exercise in those with lung conditions. Breathlessness is a very common symptom reported by people presenting to hospital with COVID-19 and loss of physical fitness will be very common. Using existing pulmonary rehabilitation programmes as a model, we have developed a tele-rehabilitation programme (a programme that will be delivered using video link to overcome the challenges faced by social distancing and shielding advice) for people that have been critically ill with COVID-19. In order to prove whether people benefit from this tele-rehabilitation programme after being admitted to hospital following COVID-19 we would need to perform a large clinical trial. However, before doing this it is important for us to answer some key questions: - How many people that have been admitted to hospital and needed intensive care treatment for COVID-19 still report breathlessness, fatigue, cough and limitation of activities after being discharged from hospital? - Is it possible to recruit these people to a trial of tele-rehabilitation after hospital discharge? - Are people willing and able to perform tele-rehabilitation in their own home using video-link to connect with their therapist? - Are there other rehabilitation needs that are commonly encountered by people requiring intensive care treatment for COVID-19 that could be addressed by tele-rehabilitation that the programme doesn't currently address? Investigators will perform a small study called a feasibility trial to answer these questions and gather some early information about possible benefits of tele-rehabilitation. Based on our understanding of other similar diseases, doctors and therapists think that people will benefit from rehabilitation after COVID-19. The investigators therefore want to test a trial design that makes sure that everyone gets the treatment. This type of trial is called a feasibility, wait-list design randomised controlled trial. People with breathlessness and some limitation of activities will be selected at random to receive tele-rehabilitation within 2 weeks or to wait 6-8 weeks before starting. how many people were eligible to take part, how many agreed to take part and the symptoms and rehabilitation needs that they have will be assessed. Investigators will then monitor symptoms and ability to exercise at the start and end of the trial and before and after tele-rehabilitation.

    NCT04511962
    Conditions
    1. Pulmonary Disease
    Interventions
    1. Other: Tele-Pulmonary rehabilitation
    MeSH:Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: The proportion of the total patients contacted, that meet the intieligibility criteria and give consent to take part Data quality: completion of clinical outcomes (questionnaires and other assessments) at each time point and patterns of missing data for the study measures. Intervention: Adherence in delivery and uptake documented in the clinical record.

    Measure: Recruitment - contact to consent ratio

    Time: through study completion an average of a year

    Description: The proportion of patients consented to the study that do not meet the eligibility criteria

    Measure: Recruitment - screen failure rate

    Time: through study completion an average of a year

    Description: The number patients recruited over the designated time frame

    Measure: Recruitment rate

    Time: through study completion an average of a year

    Description: The proportion of consented patients that complete the study

    Measure: Recruitment retention

    Time: through study completion an average of 16 months

    Secondary Outcomes

    Description: The Modified Medical Research Council Dyspnoea Scale is a self rating tool to measure the degree of disability that breathlessness poses on day to day activities on a scale of 0-4; the higher the score the worse the outcome. A comparison of Change in MMRC dyspnoea scale from baseline to post 8 weeks tele rehab within the group and between fast track and wait list group.

    Measure: The Modified Medical Research Council (MMRC) Dyspnoea Scale

    Time: 8 weeks

    Description: The Numerical Rating Scale is a self rating tool to measure breathlessness on a 0-10 scale; a higher number indicates a worse outcome. A comparison of change in numerical scale from baseline to post 8 weeks tele rehab within the group and between fast track and wait list group

    Measure: Numerical Rating Scale (NRS) of breathlessness

    Time: 8 weeks

    Description: The Cough Visual Analogue Scale is a self rating assessment of cough on an 0-100mm scale: the higher the number reported the worse the symptom. A comparison of Change in cough visual analogue scale from baseline to post 8 weeks tele rehab within the group and between fast track and wait list group

    Measure: Cough Visual analogue Scale (VAS)

    Time: 8 weeks

    Description: The EQ-5D-5L questionnaire assesses the patients current health status and consists of two elements: 1. Visual Analogue Scale with a range of 0-100mm- the higher the number the worse the outcome 2. A quality of life questionnaire split into 5 domains which generates a 5 digit code ranging from 11111 to 55555 with the higher number indicating a worse outcome. A comparison of Change in EQ-5D-5L quality of life questionnaire from baseline to post 8 weeks tele rehab within the group and between fast track and wait list group

    Measure: EQ-5D-5L questionnaire

    Time: 8 weeks

    Description: The Hospital Anxiety and Depression scale consists of two sub scales anxiety and depression with a range of between 0-21, the higher score indicating the worse outcome. A comparison of Change in Hospital anxiety and depression questionnaire from baseline to post 8 weeks tele rehab within the group and between fast track and wait list group

    Measure: Hospital Anxiety and Depression scale

    Time: 8 weeks

    Description: comparison of sit to stand test from baseline to post 8 weeks tele rehab within the group and between fast track and wait list grou

    Measure: Sit to stand test

    Time: 8 weeks
    13 EARSATS-19: In-ear Measurement of Blood Oxygen Saturation in COVID-19 Follow up

    TITLE EARSATS-19: In-ear measurement of blood oxygen saturation in COVID-19 follow up DESIGN Non-inferiority study AIMS To evaluate qualitative and quantitative performance of in-ear SpO2 monitoring against the gold standard right finger-clip pulse oximeter -- towards validation for use in COVID-19 in the acute ambulatory and long-term monitoring setting OUTCOME MEASURES In-ear SpO2 compared with gold-standard finger-clip pulse oximeter: Correlation between SpO2 measurements at rest Correlation between SpO2 measurements during 6 minute walk test Signal quality during 6 minute walk test Qualitative evaluation of clinical and patient user acceptability using questionnaires POPULATION 30 patients attending COVID-19 follow-up clinic and 30 patients with chronic lung disease attending routine outpatient investigations ELIGIBILITY Aged 18 and above, no upper age limit Able to give informed consent No abnormal ear anatomy. DURATION 12 months

    NCT04529408
    Conditions
    1. Covid19
    2. Pulmonary Disease
    Interventions
    1. Device: EarSats Pulse Oximeter Probe
    MeSH:Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: Mean error and root mean square error; measurements for statistical significance using a paired t-test.

    Measure: In-Ear vs finger SpO2

    Time: 12 months for full participant recruitment (actual head-to head comparison takes 1 minute for baseline reading and 6 minutes for 6-min walk test per patient)
    14 A Self - Guided, Internet - Based Intervention for Patients With Chronic Breathlessness (SELF-BREATHE): Feasibility Randomised Controlled Trial

    A feasibility RCT comprising two groups: 1. Intervention (SELF-BREATHE in addition to standard NHS care) 2. Control group (standard / currently available NHS care)

    NCT04574050
    Conditions
    1. Cancer
    2. COPD
    3. Asthma
    4. Bronchiectasis Adult
    5. Interstitial Lung Disease
    6. Cystic Fibrosis
    7. Chronic Heart Failure
    8. Sickle Cell Disease
    9. Renal Failure
    10. Liver Failure
    11. Post COVID-19
    12. Dyspnea
    Interventions
    1. Other: SELF-BREATHE
    MeSH:Cystic Fibrosis Liver Failure Lung Diseases Dyspnea Bronchiectasis Lung Diseases, Interstitial Anemia, Sickle Cell
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Bronchiectasis Dyspnea Hepatic failure Interstitial pneumonitis Respiratory distress

    Primary Outcomes

    Description: The number of patients recruited into this study over a 12-month period

    Measure: Feasibility: the number of patients recruited into this study over a 12-month period

    Time: 12 months
    15 Early Nintedanib Deployment in COVID-19 Interstitial Fibrosis

    This is a collaborative study between Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim Pharmaceuticals to determine the effect of Nintedanib on slowing the rate of lung fibrosis in patients who have been diagnosed with COVID-19, and have ongoing lung injury more than 4 weeks out from their diagnosis.

    NCT04619680
    Conditions
    1. Pulmonary Fibrosis
    2. Interstitial Lung Disease
    3. Respiratory Disease
    Interventions
    1. Drug: Nintedanib
    2. Drug: Placebo
    MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial Respiration Disorders Respiratory Tract Diseases Fibrosis
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

    Primary Outcomes

    Description: Change in Forced Vital Capacity (FVC) at 180 days as compared to baseline. Forced vital capacity (FVC) is the amount of air that can be forcibly exhaled from your lungs after taking the deepest breath possible, as measured by spirometry.

    Measure: Change in Forced Vital Capacity (FVC)

    Time: Baseline and 180 days

    Secondary Outcomes

    Description: Death within 90 days and 180 days from enrollment due to a respiratory cause

    Measure: Number of deaths due to respiratory cause

    Time: within 90-180 days

    Description: Quantitative Change in chest CT visual score graded by blinded chest radiologists. Data driven texture analysis (DTA) is a patented deep learning method to quantify lung fibrosis. DTA score is reported in percentage ranging from 0% to 100%. A minimally clinical important difference when comparing CT scans from the same subject is 4%. A higher percentage suggests worsening lung injury.

    Measure: Chest CT visual score

    Time: 180 days

    Description: The Saint George's Respiratory Questionnaire (SGRQ) is a self-reported disease-specific, health-related quality of life (QOL) questionnaire. 50-item instrument. Scores range from 0 to 100, with higher scores indicating more limitations.

    Measure: St. George's Respiratory Questionnaire (SGRQ)

    Time: Day 90

    Description: The Saint George's Respiratory Questionnaire (SGRQ) is a self-reported disease-specific, health-related quality of life (QOL) questionnaire. 50-item instrument. Scores range from 0 to 100, with higher scores indicating more limitations.

    Measure: St. George's Respiratory Questionnaire (SGRQ)

    Time: Day 180

    Description: The King's Brief Interstitial Lung Disease (KBILD) questionnaire is a self-administered, ILD-specific measure of health-related quality of life, comprising 15 items with three domains (Psychological (KBILD-P), Breathlessness and activities (KBILD-B), and Chest symptoms (KBILD-C)) combined in a total score (KBILD-T). The KBILD domain and total score ranges are 0-100; 100 represents best health status.

    Measure: King's Brief Interstitial Lung Disease (KBILD)

    Time: Day 90

    Description: The King's Brief Interstitial Lung Disease (KBILD) questionnaire is a self-administered, ILD-specific measure of health-related quality of life, comprising 15 items with three domains (Psychological (KBILD-P), Breathlessness and activities (KBILD-B), and Chest symptoms (KBILD-C)) combined in a total score (KBILD-T). The KBILD domain and total score ranges are 0-100; 100 represents best health status.

    Measure: King's Brief ILD (KBILD)

    Time: Day 180

    Description: The LCQ is a 19 item questionnaire that assesses cough-related QOL. It has 3 domains (physical, psychological and social). The domain scores range from 1-7 and total score range is 3-21 with a higher score indicating a better quality of life.

    Measure: Leicester Cough Questionnaire (LCQ)

    Time: Day 90

    Description: The LCQ is a 19 item questionnaire that assesses cough-related QOL. It has 3 domains (physical, psychological and social). The domain scores range from 1-7 and total score range is 3-21 with a higher score indicating a better quality of life.

    Measure: Leicester Cough Questionnaire

    Time: Day 180

    Description: The (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status. Scores range from 0 - 100, with higher scores indicating less disability.

    Measure: Short Form (SF) 36 Health Survey

    Time: Day 90

    Description: The (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status. Scores range from 0 - 100, with higher scores indicating less disability.

    Measure: SF 36 Health Survey

    Time: Day 180

    Description: Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression. 14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms). Scores for the entire scale is 0 to 42, with higher score indicating more distress.

    Measure: Hospital Anxiety and Depression Scale (HADS)

    Time: Day 90

    Description: Questionnaire with 7 items for anxiety and 7 items for depression, each item is scored on a 4 point response 0 - 3, with full range from 0 to 42, with higher score indicating more severe anxiety or depression. 14-items scale with responses scored from 0-3, scores for each subscale from 0 (normal) to 21 (severe symptoms). Scores for the entire scale is 0 to 42, with higher score indicating more distress.

    Measure: Hospital Anxiety and Depression Scale (HADS)

    Time: Day 180

    Description: Number of participants with Increase in liver transaminases

    Measure: Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal

    Time: day 90

    Description: Number of participants with Increase in liver transaminases

    Measure: Number of participants with Increase in liver transaminases (AST and ALT) > 3 times the upper limit of normal

    Time: day 180

    Description: Number of participants with Thrombotic events: venous or arterial thrombosis

    Measure: Number of participants with Thrombotic events

    Time: day 90

    Description: Number of participants with Thrombotic events: venous or arterial thrombosis

    Measure: Number of participants with Thrombotic events

    Time: day 180

    Description: Number of participants with 10% weight loss

    Measure: Number of participants with 10% weight loss over 90 days

    Time: day 90

    Description: Number of participants with 10% weight loss

    Measure: Number of participants with 10% weight loss over 90 days

    Time: day 180

    Description: Number of participants with Nausea/emesis/diarrhea not responsive to anti-emetics and anti-motility agents

    Measure: Number of participants with GI events

    Time: day 90

    Description: Number of participants with Nausea/emesis/diarrhea not responsive to anti-emetics and anti-motility agents

    Measure: Number of participants with GI events

    Time: day 180
    16 Chronic Lung Disease and COVID-19: Understanding Severity, Recovery and Rehabilitation Needs (LAUREL Study)

    This is study is comprised of three approaches. First, the investigators will conduct a retrospective cohort study to provide rapid initial guidance for rehabilitation programs to anticipate care needs of COVID-19 survivors. The investigators will also conduct a mixed-methods study and follow COVID-19 patients with repeated surveys to determine patient-reported functional outcomes, health recovery and rehabilitation needs after COVID-19. The investigators will recruit patients and their informal caregivers for interviews to assess their function and rehabilitation needs. Lastly, the investigators will examine the feasibility and acceptability of a virtually delivered, home-based rehabilitation intervention for survivors of COVID-19, with components based on an individual patient's need.

    NCT04628039
    Conditions
    1. COVID-19
    Interventions
    1. Other: Rehabilitation-focused program
    MeSH:Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: Profile for health-related quality of life. The investigators will summarize this measure with a visual analog score (VAS). The VAS ranges from 0 to 100mm (where 0="the worst health you can imagine"; 100="the best health you can imagine").

    Measure: EuroQol 5 Dimension 5 Level (EQ-5D-5L) visual analog score

    Time: Change in score from 3-8 weeks (after diagnosis or discharge to home) to months 6 and 12

    Description: Global assessment of overall physical and psychosocial function. The overall score for disability will be calculated using item-response-theory (IRT) based scoring. This scale ranges from 0 to 100 (where 0 = no disability; 100 = full disability).

    Measure: WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)

    Time: Change in score from 3-8 weeks (after diagnosis or discharge to home) to months 6 and 12

    Description: Profile for health-related quality of life. We will summarize this measure with an overall utility index. The utility index ranges from less than 0 to 1(where <0="worse than death";1=full health).

    Measure: EuroQol 5 Dimension 5 Level (EQ-5D-5L) overall utility index

    Time: Change in score from 3-8 weeks (after diagnosis or discharge to home) to months 6 and 12
    17 Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19.

    A study is being conducted to evaluate the efficacy and safety of Longidaze for the prevention and treatment of post-inflammatory pulmonary fibrosis and interstitial lung disease following COVID-19.

    NCT04645368
    Conditions
    1. Fibroses, Pulmonary
    Interventions
    1. Drug: bovhyaluronidase azoxymer
    MeSH:Lung Diseases Pulmonary Fibrosis Lung Diseases, Interstitial Fibrosis
    HPO:Abnormal lung morphology Abnormal pulmonary Interstitial morphology Interstitial pneumonitis Pulmonary fibrosis

    Primary Outcomes

    Description: The severity of pulmonary tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group according to the results of a blinded central laboratory

    Measure: The severity of lung tissue lesions with fibrosis and interstitial changes on day 75

    Time: Day 0, Day 75

    Secondary Outcomes

    Description: The severity of lung tissue damage by fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 6 months in relation to the baseline values of the indicator in patients of the Longidaze® group in comparison with the the dynamic observation group (according to the results of a blinded central laboratory)

    Measure: The severity of lung tissue damage by fibrosis and interstitial changes (%) on day 180

    Time: Day 0, Day 180

    Description: The severity of lung tissue lesions with fibrosis and interstitial changes (%) according to high resolution computed tomography examination relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group (according to the results of the local laboratory)

    Measure: The severity of lung tissue lesions with fibrosis and interstitial changes (%) on day 75 and day 180

    Time: Day 0, Day 75, Day 180

    Description: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) based on the high-resolution computed tomography images analyzed by the Botkin.AI program (artificial intelligence) and then verified by a specialist after 2.5 months and 6 months from the beginning of observation in relation to the baseline values of indicators in patients of the Longidaze® group in comparison with the dynamic observation group

    Measure: The severity of lesions of the lung tissue with fibrosis and interstitial changes and indicators: frosted glass, hydrothorax, consolidation (%) images analyzed by the Botkin.AI program (artificial intelligence)

    Time: Day 75, Day 180

    Description: Change in forced vital capacity FVC (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group

    Measure: Change in forced vital capacity (FVC)

    Time: Day 0, Day 75, Day 180

    Description: Change in the diffusion capacity of the lungs (%) relative to the baseline value after 2.5 months and 6 months in patients of the Longidaze® group compared with the the dynamic observation group

    Measure: Change in the diffusion capacity of the lungs

    Time: Day 0, Day 75, Day 180

    Description: Change in the degree of dyspnea on the MMRC scale from baseline after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group. MMRC scale (Modified Medical Research Council scale) 0 - no - Dyspnea does not bother, except for very intense exercise - mild - Shortness of breath bothers with brisk walking or climbing a small elevation - moderate to severe - Shortness of breath results in slower walking compared to other people of the same age, or need to stop while walking at normal pace on a level surface - Severe - Shortness of breath makes you stop when walking about 100 m or after a few minutes of walking on a flat surface - very severe - Shortness of breath makes it impossible to leave the house or appears when dressing and undressing

    Measure: Change in the degree of dyspnea on the MMRC scale

    Time: Day 0, Day 75, Day 180

    Description: Changes in SpO2 of capillary blood relative to the initial value after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Changes in capillary blood oxygen saturation (SpO2)

    Time: Day 0, Day 75, Day 180

    Description: Changes in the covered footage in the 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Changes in the covered footage in the 6-minute walk test

    Time: Day 0, Day 75, Day 180

    Description: Changes in capillary blood saturation (SpO2) after a 6-minute walk test after 2.5 months and 6 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Changes in capillary blood saturation (SpO2) after a 6-minute walk test

    Time: Day 0, Day 75, Day 180

    Description: Change in the residual volume of the lungs after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Change in the residual volume of the lungs

    Time: Day 0, Day 75

    Description: Change in the total lung capacity after 2.5 months in patients of the Longidaze® group compared with the dynamic observation group.

    Measure: Change in the total lung capacity

    Time: Day 0, Day 75

    Description: Change in inspiratory capacity after 2.5 months in patients of the Longidaze® group compared with dynamic observation group

    Measure: Change in inspiratory capacity

    Time: Day 75
    18 Feasibility of Using a Home-Based High Frequency Chest Wall Oscillation Device (AffloVest) in At-Risk Respiratory Patients to Decrease Acute Respiratory Care Burden During the COVID-19 Pandemic

    The purpose of the study is to investigate the addition of high frequency chest wall oscillation (HFCWO) therapy to the prescribed care regimen to support the diaphragm during airway clearance among post-COVID patients with COPD and chronic productive cough as a way to limit the advancement of pulmonary symptoms and need for critical services during recovery from COVID-19.

    NCT04654481
    Conditions
    1. Chronic Obstructive Pulmonary Disease
    2. Chronic Cough
    3. Covid19
    Interventions
    1. Device: HCFWO
    2. Other: Standard Care Plus Monitoring
    MeSH:Lung Diseases Lung Diseases, Obstructive Pulmonary Disease, Chronic Obstructive
    HPO:Abnormal lung morphology Chronic pulmonary obstruction Pulmonary obstruction

    Primary Outcomes

    Description: Change in forced expiratory volume in one second (FEV1) as compared to baseline, measured by home spirometer.

    Measure: Change in forced expiratory volume in one second (FEV1)

    Time: Baseline and up to 90 Days

    Description: Changes in oxygen saturation from baseline as measured by pulse oximeter. Normal oxygen range is 95 to 100 percent and low oxygen range is under 90 percent.

    Measure: Change in Oxygen Saturation level

    Time: Baseline and up to 90 Days

    Description: Changes in basal temperature as measured by digital thermometer. Fever is indicated at 100.4 F (38 C) or higher.

    Measure: Change in Presence of Fever

    Time: Baseline and up to 90 Days

    Secondary Outcomes

    Description: CAP Symptom Questionnaire records how much the patient rated the bothersomeness of the symptom. Each item is scored as "0" (Patient did not have this symptom), "1" (Not at All) to "5" (Extremely). Full range scale from 0 to 90, higher score indicating patient experiencing more frequent or more severe symptoms.

    Measure: Change in Presence of pneumonia symptoms via Community Acquired Pneumonia (CAP) Symptom Questionnaire

    Time: Baseline and up to 90 Days

    Description: The QOL-B is a disease-specific questionnaire that measures symptoms, functioning, and health-related quality of life relevant to patients with bronchiectasis. Scores are generated from 37 items that fall on 8 domains: Physical Functioning, Role Functioning, Vitality, Emotional Functioning, Social Functioning, Treatment Burden, Health Perceptions, and Respiratory Symptoms. All subscales and the full range scale are standardized to score from 0 to 100, with higher scores indicating better enjoyment and satisfaction with specific life domains.

    Measure: Change in Quality of life via Quality of Life Questionnaire-Respiratory (QOL-B)

    Time: Baseline and up to 90 Days

    Description: The PHQ-8 is the depression module, which scores each of the eight DSM-IV criteria as "0" (not at all) to "3" (nearly every day). Full scale from 0-24, with higher score indicating more severe symptoms.

    Measure: Change in Mental health screening via Personal Health Questionnaire Depression Scale (PHQ-8)

    Time: Baseline and up to 90 Days

    Description: The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire that asks user to rank how often they have been bothered by seven problems over the past two weeks from "0" (not at all) to "3" (nearly every day). Full scale from 0-21, with higher score indicating more symptoms.

    Measure: Change in Mental health screening via General Anxiety Disorder-7 (GAD-7)

    Time: Baseline and up to 90 Days

    Description: Eight questions that are specific to recent literature describing patients' experiences of symptoms during COVID. They are rated on a frequency scale from "never" to "always," using a 1-4 point scale. Full scale range from 8 to 32, with higher scores indicating more frequent symptoms.

    Measure: Change in COVID Symptom Checklist

    Time: Baseline and up to 90 Days

    Description: Amount of time used per week in minutes

    Measure: AffloVest Usage

    Time: 90 Days
    19 Comparison of the Efficacy and Safety of Two Corticosteroid Regimens in the Treatment of Diffuse Lung Disease After Coronavirus Disease 2019 (COVID-19) Pneumonia

    A proportion of patients with COVID-19 pneumonia have a prolonged course of illness. Some of these patients continue to have considerable respiratory symptoms or persistent hypoxemia. The CT abnormalities in these patients are often a combination of ground-glass opacities and patchy multifocal consolidation consistent with a pattern of OP. In several patients, these radiologic abnormalities persist. As with other forms of OP, patients with post-COVID OP or post COVID diffuse lung disease (PC-DLD) may benefit from treatment with oral glucocorticoids. The ideal dose of glucocorticoids for treating PC-DLD is unknown. In this study, we aim to compare the efficacy and safety of a medium dose and a low dose of prednisolone (as the initial dose) for the treatment of post-COVID. diffuse lung disease.

    NCT04657484
    Conditions
    1. Post COVID-19 Diffuse Lung Disease
    Interventions
    1. Drug: Medium dose prednisolone
    2. Drug: Low dose prednisolone
    MeSH:Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: Complete response is defined as complete disappearance or ≥90% reduction in the lung parenchymal abnormalities on a high-resolution CT scan

    Measure: Proportion of subjects with a complete radiologic response

    Time: 6 weeks

    Secondary Outcomes

    Description: Complete response is defined as complete disappearance or ≥90% reduction in the lung parenchymal abnormalities on a high-resolution CT scan. Good response is defined as ≥50% but less than 90% reduction in the lung parenchymal abnormalities on a high-resolution CT scan.

    Measure: Proportion of subjects with a complete or good response radiologic response

    Time: 6 weeks

    Description: Complete or good radiologic resolution along with no oxygen desturation on exercise testing

    Measure: Proportion of subjects with a good composite response

    Time: 6 weeks

    Description: Forced vital capacity will be measured using spirometry. The predicted value will be calculated based on standard reference equations.

    Measure: Forced vital capacity as a percentage of the predicted

    Time: 6 weeks

    Description: The change in resting oxygen saturation (measured by pulse oximetry) from the day of randomization to 6 weeks

    Measure: Change in resting oxygen saturation

    Time: 6 weeks

    Description: Oxygen desaturation will be defined as a fall in oxygen saturation by 4% or more on exercise testing (by one-minute sit-to-stand test and six-minute walk test)

    Measure: Proportion of subjects with oxygen desaturation on exercise testing

    Time: 6 weeks

    Description: The change in dyspnea score assessed using the modified Medical Research Council (mMRC) scale from the day of randomization to 6 weeks

    Measure: Change in dyspnea score

    Time: 6 weeks

    Description: Severity of dyspnea assessed using the FACIT-Dyspnea scale

    Measure: Severity of dyspnea

    Time: 6 weeks

    Description: Respiratory health status assessed using the King's Brief ILD questionnaire

    Measure: Respiratory health status

    Time: 6 weeks

    Description: Health-related quality of life assessed using Short Form-36 questionnaire

    Measure: Health-related quality of life

    Time: 6 weeks

    Description: The adverse effects of treatment (acne, weight gain, hyperglycemia, hypertension, abdominal pain, dyspepsia, Cushingoid facies, skin thinning and bruising, mood changes, muscular weakness and any other adverse effects related to prednisolone)

    Measure: Adverse effects of prednisolone

    Time: 6 weeks
    20 Evaluation of the Feasibility and Safety of a Pulmonary Tele-rehabilitation Program in the Times of COVID-19

    Chronic pulmonary disease like interstitial lung disease (ILD) and chronic obstructive lung disease (COPD) are a significant health problem in Canada and around the world. In addition to the respiratory impairment resulting to a progressive dyspnea, these diseases are also characterized by a decrease in exercise tolerance and muscle dysfunction which affect the patient's quality of life. Respiratory rehabilitation is the cornerstone of the management of chronic disease and it includes a set of personalized care mainly delivered in person by a transdisciplinary team and with the objectives of reducing the symptoms felt by the participants and improving their physical and psychosocial condition. The current containment due to the COVID-19 pandemic increase the sedentary behavior of patients and prevents the holding of any respiratory rehabilitation activity. In this context, tele-rehabilitation appears to be a particularly well-suited solution because it would make it possible to offer a respiratory rehabilitation in a safe and effective manner while minimizing contact with the participants. Although some studies support the feasibility of this intervention, more data is needed to validate its routine clinical application. The main objective of this study is to verify the safety and the feasibility of delivering pulmonary rehabilitation treatments entirely at home via a telerehabilitation patform developed at the Institut universitraire de cardiologie et de pneumologie de Québec (IUCPQ), and document its effectiveness in people with chronic respiratory disease. The secondary objectives will be: 1) to explore the effects of a telerehabilitation programm on exercise tolerance, muscle function, functional capacity and quality of life, and 2) to assess the satisfaction of participants and health care providers with telerehabilitation.

    NCT04658979
    Conditions
    1. Chronic Pulmonary Disease
    Interventions
    1. Other: Pulmonary tele-rehabilitation
    MeSH:Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: Patient's satisfaction will be evaluated by a questionnaire including 7 questions on his feeling of competence with regard to the program, based on an 8-point Likert scale (0 to 7).

    Measure: Feasability - Patients´ satisfaction with the program between baseline and the up to 12 weeks follow-up

    Time: 12 weeks

    Description: Health care professionals' receptivity towards the tele-rehabilitation will be assess by 18 questions based on an 6-point scale (0 to 5).

    Measure: Feasability - Health care professionals' receptivity

    Time: 12 weeks

    Description: Patient's satisfaction will be evaluated by a questionnaire including 23 questions based on a 4-point scale (1 to 4).

    Measure: Feasibility - Patients' satisfaction with the health care received

    Time: 12 weeks

    Secondary Outcomes

    Description: For the COPD participants the quality of live will be evaluated with the COPD Assessment test (CAT) and fort he ILD participants with the Kings' Brief Interstitial Lung Disease (K-BLID) questionnaire. CAT = K-BLID = 15 questions rate between 1 to 7 (maximal score = 105 = better quality of life; minimal score = 15 = worse quality of life)

    Measure: Quality of life by questionnaire

    Time: 12 weeks

    Description: The dyspnea level will be evaluated with the MRC questionnaire = 4 questions If the patient answer yes to the first question he continue to the next question, if he answer no the questionnaire is finish. The further he goes in the questionnaire, worse the breathlessness score is.

    Measure: Dyspnea level

    Time: 12 weeks

    Description: The exercise capacity will be evaluated by the 6-minutes stepper test before and after the program, the result will be the number of cycle complet

    Measure: Exercise capacity

    Time: 12 weeks

    Description: The exercise capacity will be evaluated by the 1-minute sit to stand test before and after the program, the result will be the number of complet sit to stand.

    Measure: Exercise capacity

    Time: 12 weeks

    Description: The functional capacity will be evaluated by the Short Physical Performance Battery test (SPPB) test before and after the program, the result will be the total on 12.

    Measure: Functionnal capacity

    Time: 12 weeks

    Description: The functional capacity will be evaluated by the hand grip test before and after the program and measured in kilograms.

    Measure: Functionnal capacity

    Time: 12 weeks

    Description: The functional capacity will be evaluated by the maximum voluntary contraction force of the quadriceps before and after the program.

    Measure: Functionnal capacity

    Time: 12 weeks

    Description: The anxiety will be assess by the Hospital Anxiety and Depression scale (HAD). Total of 14 questions (maximal score = 42 = worse; minimal score = 0= better) where 7 questions is for the anxiety score(maximal score = 21 = worse; minimal score = 0= better)

    Measure: Anxiety

    Time: 12 weeks

    Description: The depression will by assess by Hospital Anxiety and Depression scale.14 questions (maximal score = 42 = worse; minimal score = 0= better) where 7 questions is for the depression score (maximal score = 21 = worse; minimal score = 0= better)

    Measure: Depression

    Time: 12 weeks
    21 Lung Ultrasound in COVID-19 Infection Screening for Patients With Indication of Emergency Surgery

    The first case of COVID-19 was identified on December 19 and the world is actually experiencing a pandemic. The surgical procedure in patients with SARS-CoV-2 infection involves the exposure of other patients and the group of health workers who face the care of the patient. Thus, screening with lung ultrasound is an alternative to identify patients with an established or suspected infection that requires urgent surgery. Therefore, the aim of this study is to determinate the operational characteristics of lung ultrasound during the screening process for SARS-CoV-2 infection in patients with an indication for urgent surgery.

    NCT04661631
    Conditions
    1. Ultrasonography
    2. Lung Diseases
    3. Surgical Procedure
    4. Covid19
    5. Severe Acute Respiratory Syndrome Coronavirus 2
    Interventions
    1. Diagnostic Test: Lung ultrasound
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Lung Diseases
    HPO:Abnormal lung morphology

    Primary Outcomes

    Description: To identify the best cut-off point from lung ultrasound that allows the discrimination of suspected cases of active SARS-CoV-2 infection in patients undergoing an emergency surgical procedure since May 2020 at Fundación Valle del Lili Hospital, Cali, Colombia.

    Measure: The best cut-off point for lung ultrasound to discriminate suspected cases of active SARS-CoV-2 infection

    Time: 14 days

    Secondary Outcomes

    Description: Identify the prevalence of active SARS-CoV-2 infection in the group of patients undergoing an emergency surgical procedure.

    Measure: Prevalence of active SARS-CoV-2 infection

    Time: 14 days

    Description: Calculate the operational characteristics of lung ultrasound for the diagnosis of SARS-CoV-2 infection in the studied group of patients.

    Measure: Operational characteristics of lung ultrasound

    Time: 14 days

    Description: Calculate the operational characteristics of each of suspicious lung ultrasound findings for the diagnosis of SARS-CoV-2 infection in the group of patients studied

    Measure: Operational characteristics of each of suspicious lung ultrasound findings

    Time: 14 days

    Description: Identify the cut-off point resulting from the lung ultrasound score that discriminates between patients with suspected active SARS-CoV-2 infection.

    Measure: Cut-off point resulting from the lung ultrasound score

    Time: 14 days

    HPO Nodes


    HP:0002088: Abnormal lung morphology
    Genes 1425
    KMT2D SMARCB1 ABCA12 MAT2A TNFSF11 TRAIP MAGEL2 DNAAF1 NFE2L2 MITF NFKB2 LCK MAGEL2 SGCG ALG9 TECPR2 GTF2IRD1 CALCRL KAT6B CHAMP1 OFD1 CTRC SCNN1G CD247 MGP TGFBR2 SPINK5 CTPS1 RASA2 NHLRC2 PHGDH RTEL1 NTRK1 NGLY1 ARVCF SLC2A10 RELB ZNF341 RSPH9 FCN3 NELFA RREB1 NAA10 MALT1 HPGD CFTR GLI1 OCA2 LETM1 NPHP3 PIK3CD FSHR FMO3 USP9X TCF4 WDR35 PRSS1 HLA-DPA1 DNAH11 RIT1 ZAP70 STK11 NKX2-5 UNC119 CDC45 BUB1B SNAI2 WAS SIM1 GNPTAB DYNC2H1 FOXH1 CFAP221 TARS1 NF1 NEB LAMB2 TTC7A CCR6 RARA ACTL6B MYO5A CD81 ADNP TNFRSF13B SEC24C TBX1 MYH6 COL3A1 TSC1 CYBA HLA-DPB1 TERT GNS FOXH1 EVC2 LIPN KATNIP TPM2 RRAS2 TSC1 EPHB4 COL6A1 NIPBL SPAG1 FLNB IL17RA HSPG2 ITGA8 GAS1 SLC12A6 EFEMP2 CRLF1 SLC26A2 GMNN DGCR8 ACTA2 CTLA4 SLC35A1 ADAMTS3 TAPBP SLC25A24 PRKCD SPECC1L CCR6 CXCR4 HOXD13 BLM RNU4ATAC CFAP300 FOXP1 CDON CD79A TTC21B CBL RAG1 VPS51 DISP1 USB1 NUP107 NEPRO COL11A2 FLNA CR2 ACVRL1 LAMTOR2 NEK1 SNORD115-1 GLE1 MAP3K20 DNMT3B SLC26A2 FAS MKRN3-AS1 LYST PIK3R1 ACADVL LIFR TDGF1 TAPT1 RFX5 VPS33A MYRF MDM4 HRAS TBC1D24 NGLY1 GLI2 FGF8 ODAD4 CCDC40 MYH11 C11ORF95 MCM4 CTLA4 CRELD1 ZBTB24 TINF2 ECM1 CAV1 NAA10 LRRC6 PUF60 CFTR FLCN COL11A2 CR2 FOXE1 CCBE1 ELP1 TFRC AGA SMPD1 PWRN1 MMP21 IPW GATA6 LACC1 TCIRG1 SERPINF2 BLNK IFT80 FLI1 UBB KIF20A STAT1 DLL4 MBTPS2 PAX3 ELP1 SNRPN DISP1 RMRP TGFBR2 KRAS STAG2 IRF8 SIX3 SOX10 KIF1A RYR1 IGHM BTK NOTCH3 DICER1 CYP4F22 CXCR4 RSPH1 MEFV CCBE1 DNAH11 ZIC2 WDFY3 CCND1 CSF2RA POLR3A BCL6 LAMA2 SMAD4 SKIV2L STAT1 SNX10 TERT FGF8 BRAF SFTPC FOXJ1 ATP11A AICDA SHH RYR1 ODAD1 SCARB2 SIK1 HACD1 CHRNG CREBBP TNFRSF13B CITED2 OCA2 MYBPC3 NODAL NOTCH2 CFAP298 SELENON CEP57 CTLA4 TRIM28 ZIC2 ALMS1 DOK7 ODAD4 IDUA DLL1 ELN SBDS COG6 TBX6 RFXAP PEX13 TCTN3 PTPN22 DGCR6 SFTPC RAG1 INTU EDNRB FGF20 MAGEL2 DNASE1L3 RASGRP1 STRA6 IFT81 COG4 MARS1 EPM2A MESP2 TTC12 SOS1 TBC1D23 IL12A-AS1 ENG SCNN1B CSF2RA TGFB1 CCN2 FBXW11 MAN2B1 HLA-DRB1 PTCH1 NPM1 EPG5 UGP2 GLI2 GAS2L2 TSC2 PPP1CB RANBP2 SCN11A GPKOW CBL CTLA4 IL12A MESP2 IL21R CRELD1 IL17RC UMPS TERT SLC18A3 MYSM1 DSE TRPS1 PEX1 MKRN3 RTEL1 RPGR DYNC2H1 PRKG1 DSG1 ACP5 FLT4 JAK3 TCF20 EXOSC9 MIR140 DNAL1 NCF4 ACTC1 IFT80 FGFR3 ALG14 VAMP1 RTL1 ESS2 WRN TGFB1 MKS1 DYNC2LI1 EWSR1 FGF20 CD3E POU6F2 ELN IDUA SFTPA2 SFTPB ATP5F1A FANCF PLCG2 SLC29A3 NDN PIGL RAG2 RAG2 SLC46A1 SLC2A10 RET PGM3 GBA IL2RG SULT2B1 DNAJB13 JMJD1C TP53 SDR9C7 BUB1 MSN MYOD1 FCGR3A SHROOM4 PNP COQ7 ACTA1 ERF MYSM1 ZEB2 ETFDH AGTR1 LEPR TBX1 PIGT FLNC DGCR2 NCF4 ODAD2 IFT172 RFXANK KAT6B DNAI1 GBA NEK10 DNAI1 KIAA0586 MPLKIP CCNQ MDM2 AGA LAMC2 RAG2 LEPR IL17F DCLRE1C SPIDR LIMK1 PEPD CCN2 ITGA3 MYT1L ZBTB24 STAT5B NCF1 CD3D EP300 RIT1 IL2RB GLI2 DICER1 COL6A3 FBLN5 TASP1 DCLRE1C FARSA CDC42 PYROXD1 IL7R TBC1D24 PLCG2 GAA ODAD3 STAT4 LTBP4 NFKBIA PKHD1 IL17RA KRAS MCTP2 BPTF IGLL1 SCNN1A ODAD3 TK2 PSMC3IP TPM3 RNF113A MBTPS2 IGHM PDGFRB RAF1 FASLG CCDC39 MUSK FAM111B NDUFAF6 TRIP4 MS4A1 SMN1 MUSK PRKAG2 SMARCC2 HLA-DRB1 CFH LEP CYBB LMNA PSMD12 NEU1 CD3E PTPRC STAT3 PLG CHRNA1 FOXH1 TNNI3 PRKAR1A TYK2 LOX FLCN NEK9 ORC6 RNF168 PTPN11 CARD11 CD3G LONP1 TGFBR1 CC2D2A GNPTAB IDUA TREX1 CYBB NBN NRAS LPIN2 DNAAF6 TGIF1 WAC ADA FBN1 STAT3 SETBP1 ACTA1 STRA6 CD3D STAT3 ZMIZ1 ETFB RSPH4A SFTPC HLA-B TBX5 TSC1 DNMT3B A2ML1 RPL10 RPL10 MEFV TP53 ITCH BRCA2 IRF2BP2 GAS1 ASXL1 NEK10 CCDC22 SAMD9 MYH7 WNT4 DOCK3 CD247 CFI RCBTB1 UFD1 TREX1 ASAH1 INPPL1 NOTCH2 SERPINF2 MECP2 DKC1 KAT6B MEFV GLDN CHRNG HYDIN CDT1 DNAAF2 IL6R LAMB3 NFKB1 RUNX2 IL1RN GLI3 IRAK1 KANSL1 DLL3 PTCH1 TGFBR1 NDUFB10 REN TDGF1 ABCA3 RAG1 KIF11 FGFR1 UBE2A MYOD1 NFKB2 PIK3CD SMN1 FREM2 TGIF1 LAT HELLS ZEB2 RSPH9 NSDHL SERPINH1 MTHFD1 FAM13A SETD2 PAX6 SOX18 SMARCD1 OCRL SLC52A3 BMPR2 DZIP1L TDGF1 WDR1 ALB CD28 ADA2 RAPSN DLL1 RBPJ WDR19 HLA-DRB1 SHH BMPER MYLK TMEM94 SIX3 PML TGFB3 MYL2 STAG2 TBL1XR1 FBN1 EFL1 TERC BUB3 HES7 FOXC2 RBM10 CFAP410 MASP2 TRIP13 GLB1 MEG3 MYH3 LIG4 PARN RHOH NFKB2 EDARADD DNAAF6 BCR RNF125 TLL1 DCLRE1C SCNN1A GPC3 ASAH1 SNAP25 NR5A1 NHP2 DNAAF5 DLL1 EXTL3 PRPS1 MAN2B1 FANCB COMT ZMYND10 FOXN1 PRKCD BLNK NTNG1 IL2RG IL7R EMG1 TRPV4 SMPD1 ETFA IRF5 NODAL WT1 NECTIN1 LAMTOR2 RAG2 ROR2 ADA FCGR2A IER3IP1 CYTB KDM6A BTNL2 WNT3 TLL1 ALOXE3 TGIF1 ASCC1 PIGN BNC1 RIPPLY2 BAP1 NOS1 NXN DSP DNAH1 ITPR1 IGH PIEZO1 CSPP1 COL3A1 ARHGAP31 MS4A1 NODAL USB1 LRRC56 NPM1 TSC2 ATP6V0A2 DHCR7 ZBTB16 EPG5 TINF2 CASP8 PRPS1 IKBKB ARID2 SHH ARID1B RLIM EGFR CDKN2A LAMA3 SFTPA1 IKZF1 CAV1 PLOD1 PRKDC LMNA JAK3 BMP2 AKT1 CFTR ELN AGT DNAAF4 ATP6V1E1 IFT140 BTK BTNL2 COPA PEPD SCNN1B KCNJ6 GAA MCIDAS PTEN SOX4 ZMYND10 UNG GATA6 DYNC2I1 PSAT1 GATA4 SLC26A2 NDN BCOR NAB2 CD81 NKX2-1 PLOD1 PLEC FUZ CRTAP FGF8 GAS1 ABCA12 REST B3GLCT IGH CLIP2 SCNN1B H19 CYBC1 ELN RAG1 ALDH18A1 MYT1L KLHL41 ACE RSPO2 CLEC7A HIRA GP1BB DRC1 GDF1 TP53 GLI3 SVBP TCIRG1 FRAS1 IRF5 GDF1 PMM2 PAFAH1B1 ZMPSTE24 TGM1 DLL1 SIX3 CCNQ TIMM8A ELN PTEN FUCA1 MYD88 SPAG1 ARID1B AGGF1 THOC2 ABCA3 ARSB CFB PORCN HFE SOX11 NOTCH1 FOXP3 TERC USP9X P4HTM DRC1 AP3B1 CBL POLA1 CDON PKHD1 TAF1 COLQ SON TRPV3 TSC1 DVL3 TCF3 TRIP4 CHEK2 FLNB STAT5B STXBP2 CREBBP NPAP1 FAM20C STK36 DOCK8 SLC7A7 DDR2 TTC37 CD8A DOCK6 CD46 CCDC65 BCL2 INPPL1 DIS3L2 MFAP5 TNFRSF13C KNSTRN RPS15A GLA SELENON LRRC6 KMT2E SLC5A7 TERT GRIP1 DYNC2I2 PTPN22 FAT4 SHH IFIH1 IL7R PARN ARHGAP31 CSF2RB CHST14 TANC2 CIITA ZIC2 FLNA G6PC3 MARS1 BACH2 ZNHIT3 DNAJC21 SH2D1A CCNO COL13A1 DISP1 IL21 HYDIN MGP IL2RA MED25 GSN FOXH1 SLC35C1 PNP PRTN3 SP110 ARID1A MEFV NOD2 SERPINA1 NHP2 MED13 FRAS1 NBN MCIDAS FCGR2B KLHL40 BLM RAG1 RRAS TAP1 SNRPN ADGRG6 NADK2 SLC26A2 DDR2 ZAP70 MAGT1 FGFR1 GATA2 ALOX12B TMEM260 IFNGR1 SMAD4 SLC7A7 NFKB1 RB1 RARB APOE GATA6 DOCK8 AP3D1 SOS2 STING1 CASP10 B2M FLCN SRP54 ZEB2 TNFRSF13C FADD C4A TTC12 TAP2 KPTN STN1 LBR SNRPN DNAI2 MRAS COL2A1 RNF168 CHRM3 CCNO CHRNG RAC1 FGFR3 LGI4 ADA NUP88 TBX20 ODAD2 BCL10 FLNA SLC25A22 ELN SMO GBA TGFB2 NUMA1 RAG2 GATA4 DNAH9 SMARCA4 TNFRSF11A IRAK4 GUSB CD40LG SCNN1G SLC34A2 DHCR7 MIF GUSB KITLG KIAA0586 GRIP1 NSD2 DPF2 SLC35A1 EIF2AK4 GBA SPP1 NCF2 MKKS GAS2L2 MYH3 TBCD HLA-DRB1 PTPN22 RAC2 DDX6 CEP57 RELA PTCH1 DNAI2 ZFPM2 TPP2 RAG1 STAT6 IFT43 KANSL1 PURA LRRC56 DNAAF1 SCNN1G IL6ST ACP5 XIAP IL2RG FANCB IGLL1 AFF4 SCNN1B BCORL1 BTK PCNT MUC5B MRPS22 CDON COG4 PRKCD PTPN11 LRRC8A PHGDH BGN DVL3 PSAP HLA-DQA1 DYNC2I2 SLC35C1 PWAR1 SLC1A4 CR2 TBCE AGRN CTCF FBLN5 VANGL1 TRIP11 NKX2-5 TSC2 GFI1 TNFSF12 GAS8 MAPK1 SLC11A1 IFNG FBN1 DNAAF2 SCNN1A ACTA1 MESP2 HABP2 NDN SLCO2A1 FOXE3 IDS PANK2 FGFR1 CHD7 DNAAF3 NABP1 DNAAF3 CFI DPM2 OCA2 PCGF2 SFTPB MANBA TNNT2 SRP54 PLVAP CD79B SOX18 INVS DYNC2LI1 RARB CD19 FOXJ1 BMPR2 PIGN LEP PKD1L1 NHLRC1 GPC6 ITCH APC2 GATA6 SCNN1A SERPINA1 ATM GBA DNAJB13 CEP120 TNFRSF1A KIAA0319L CLCN7 NSD1 CACNA1C SPEF2 PIEZO2 DYNC2I1 NKX2-5 CREBBP TBX1 TNFSF12 COL6A2 EFEMP2 RAC2 PRSS2 TBL2 CFTR IL10 CFAP298 DONSON RSPH3 ABL1 EVC SDCCAG8 DNAH5 WIPF1 PARN PDGFRA TINF2 NCF2 TNFRSF1B CEP120 FOXP1 RFC2 NPHP3 BCOR GATA4 SNORD116-1 POLR2A NOP10 CCDC103 OFD1 DNAAF5 GATA6 IL6 POLA1 PDHA1 LMNA CD19 SFTPC SIX3 LTBP3 SMPD1 SMARCD2 RIPK4 CSF2RB PSMB8 HPS4 CRKL PTH1R EP300 RSPH1 PERP ATM ABCA3 DCTN4 CLCA4 CTSC STAT3 CCND1 POLR3H TRIP13 FCGR2A MST1 MUC5B DNAH5 CDON TRAF3IP2 IDS SRSF2 SLC18A3 TRIM28 CD79A PIK3R1 GRHL3 NOP10 HPS6 WNT3 RPGR DPP9 RAF1 SCNN1G CD79B RSPO2 BCL11B IVNS1ABP ACTL6A ZIC2 AFF4 SMAD3 ITGA7 CITED2 ERCC2 RAB3GAP2 TRIP11 IL23R SPINK1 TERC RTEL1 CYBA TSC2 CITED2 GLE1 GPC3 TGFB2 SCN9A RASGRP1 FGF8 SNRPN DYNC2I1 CARD11 POLE ICOS FADD NME8 HLA-DQB1 LMNA PGM3 EOGT CDCA7 WT1 SAMD9L SMC1A ICOS GLI3 SREBF1 CHAT RFX5 FOXF1 TDGF1 CHST14 CCDC40 SMARCE1 DCLRE1C ALMS1 TLR4 NCF1 RSPH3 CYBC1 SLC25A1 PTCH1 IL2RG B3GALT6 GLI2 GAS1 TNFRSF13B TET2 NRAS WAS ZMPSTE24 EHMT1 WRAP53 FAS WDR35 HPS1 NSMCE3 TGIF1 GLUL SH3KBP1 RFXAP CARMIL2 BCOR GTF2I TNFRSF1A MAGEL2 STAT4 HGSNAT SMAD3 FBLN5 MYO9A GTF2H5 NEK8 TERT RUNX1 RYR1 FAT4 CLPB RIPK1 COL13A1 JAGN1 CIITA TBX20 CSPP1 DNAAF4 CCR1 HK1 MINPP1 UBAC2 NFIX RNU4ATAC BIRC3 WNT4 IKBKB CD27 FAS NLRC4 SFTPA2 NDN AARS2 TGFB1 DHCR24 PIK3R1 HYLS1 CREBBP CHRND ALPL ITK VHL CCDC103 GREB1L ERAP1 FARSB RAB27A NAGLU ODAD1 CTC1 ZCCHC8 TRMT1 SNRPN CEP55 PRPS1 DLL3 LYST KEAP1 GBA JAG1 NME8 MYPN STX1A TNFRSF13C FIP1L1 HERC2 ELANE CORO1A SYT2 CCDC39 CFTR GPC4 ITGA8 ICOS RFXANK KLRC4 DNASE1 DICER1 EP300 PRKAR1A MAGEL2 MLXIPL LZTR1 PIGN BMP15 HLA-DRB1 COL2A1 ADAMTS2 WDR19 ALG12 AK2 CD55 HLA-DRB1 GAS8 DKC1 NKX2-1 DLK1 SCN10A DYNC2I2 HELLPAR LMOD3 FLCN WT1 NODAL LRBA ELANE GTF2E2 SGSH GPR35 BAZ1B SFTPB TRAPPC4 PLP1 CACNA1B RSPH4A FSHR TERT CCDC65 WT1 TERC MID1 NR2F2 DHCR24 ERCC3 WASHC5 NIPAL4 LFNG VPS33A CD19 RLIM GALNS OSTM1 XIAP ASAH1 HLA-B DISP1 NAA10

    HPO

    Alphabetical listing of all HPO terms. Navigate: Correlations   Clinical Trials


    HPO Nodes


    HP:0002088: Abnormal lung morphology
    Genes 1425
    KMT2D SMARCB1 ABCA12 MAT2A TNFSF11 TRAIP MAGEL2 DNAAF1 NFE2L2 MITF NFKB2 LCK MAGEL2 SGCG ALG9 TECPR2 GTF2IRD1 CALCRL KAT6B CHAMP1 OFD1 CTRC SCNN1G CD247 MGP TGFBR2 SPINK5 CTPS1 RASA2 NHLRC2 PHGDH RTEL1 NTRK1 NGLY1 ARVCF SLC2A10 RELB ZNF341 RSPH9 FCN3 NELFA RREB1 NAA10 MALT1 HPGD CFTR GLI1 OCA2 LETM1 NPHP3 PIK3CD FSHR FMO3 USP9X TCF4 WDR35 PRSS1 HLA-DPA1 DNAH11 RIT1 ZAP70 STK11 NKX2-5 UNC119 CDC45 BUB1B SNAI2 WAS SIM1 GNPTAB DYNC2H1 FOXH1 CFAP221 TARS1 NF1 NEB LAMB2 TTC7A CCR6 RARA ACTL6B MYO5A CD81 ADNP TNFRSF13B SEC24C TBX1 MYH6 COL3A1 TSC1 CYBA HLA-DPB1 TERT GNS FOXH1 EVC2 LIPN KATNIP TPM2 RRAS2 TSC1 EPHB4 COL6A1 NIPBL SPAG1 FLNB IL17RA HSPG2 ITGA8 GAS1 SLC12A6 EFEMP2 CRLF1 SLC26A2 GMNN DGCR8 ACTA2 CTLA4 SLC35A1 ADAMTS3 TAPBP SLC25A24 PRKCD SPECC1L CCR6 CXCR4 HOXD13 BLM RNU4ATAC CFAP300 FOXP1 CDON CD79A TTC21B CBL RAG1 VPS51 DISP1 USB1 NUP107 NEPRO COL11A2 FLNA CR2 ACVRL1 LAMTOR2 NEK1 SNORD115-1 GLE1 MAP3K20 DNMT3B SLC26A2 FAS MKRN3-AS1 LYST PIK3R1 ACADVL LIFR TDGF1 TAPT1 RFX5 VPS33A MYRF MDM4 HRAS TBC1D24 NGLY1 GLI2 FGF8 ODAD4 CCDC40 MYH11 C11ORF95 MCM4 CTLA4 CRELD1 ZBTB24 TINF2 ECM1 CAV1 NAA10 LRRC6 PUF60 CFTR FLCN COL11A2 CR2 FOXE1 CCBE1 ELP1 TFRC AGA SMPD1 PWRN1 MMP21 IPW GATA6 LACC1 TCIRG1 SERPINF2 BLNK IFT80 FLI1 UBB KIF20A STAT1 DLL4 MBTPS2 PAX3 ELP1 SNRPN DISP1 RMRP TGFBR2 KRAS STAG2 IRF8 SIX3 SOX10 KIF1A RYR1 IGHM BTK NOTCH3 DICER1 CYP4F22 CXCR4 RSPH1 MEFV CCBE1 DNAH11 ZIC2 WDFY3 CCND1 CSF2RA POLR3A BCL6 LAMA2 SMAD4 SKIV2L STAT1 SNX10 TERT FGF8 BRAF SFTPC FOXJ1 ATP11A AICDA SHH RYR1 ODAD1 SCARB2 SIK1 HACD1 CHRNG CREBBP TNFRSF13B CITED2 OCA2 MYBPC3 NODAL NOTCH2 CFAP298 SELENON CEP57 CTLA4 TRIM28 ZIC2 ALMS1 DOK7 ODAD4 IDUA DLL1 ELN SBDS COG6 TBX6 RFXAP PEX13 TCTN3 PTPN22 DGCR6 SFTPC RAG1 INTU EDNRB FGF20 MAGEL2 DNASE1L3 RASGRP1 STRA6 IFT81 COG4 MARS1 EPM2A MESP2 TTC12 SOS1 TBC1D23 IL12A-AS1 ENG SCNN1B CSF2RA TGFB1 CCN2 FBXW11 MAN2B1 HLA-DRB1 PTCH1 NPM1 EPG5 UGP2 GLI2 GAS2L2 TSC2 PPP1CB RANBP2 SCN11A GPKOW CBL CTLA4 IL12A MESP2 IL21R CRELD1 IL17RC UMPS TERT SLC18A3 MYSM1 DSE TRPS1 PEX1 MKRN3 RTEL1 RPGR DYNC2H1 PRKG1 DSG1 ACP5 FLT4 JAK3 TCF20 EXOSC9 MIR140 DNAL1 NCF4 ACTC1 IFT80 FGFR3 ALG14 VAMP1 RTL1 ESS2 WRN TGFB1 MKS1 DYNC2LI1 EWSR1 FGF20 CD3E POU6F2 ELN IDUA SFTPA2 SFTPB ATP5F1A FANCF PLCG2 SLC29A3 NDN PIGL RAG2 RAG2 SLC46A1 SLC2A10 RET PGM3 GBA IL2RG SULT2B1 DNAJB13 JMJD1C TP53 SDR9C7 BUB1 MSN MYOD1 FCGR3A SHROOM4 PNP COQ7 ACTA1 ERF MYSM1 ZEB2 ETFDH AGTR1 LEPR TBX1 PIGT FLNC DGCR2 NCF4 ODAD2 IFT172 RFXANK KAT6B DNAI1 GBA NEK10 DNAI1 KIAA0586 MPLKIP CCNQ MDM2 AGA LAMC2 RAG2 LEPR IL17F DCLRE1C SPIDR LIMK1 PEPD CCN2 ITGA3 MYT1L ZBTB24 STAT5B NCF1 CD3D EP300 RIT1 IL2RB GLI2 DICER1 COL6A3 FBLN5 TASP1 DCLRE1C FARSA CDC42 PYROXD1 IL7R TBC1D24 PLCG2 GAA ODAD3 STAT4 LTBP4 NFKBIA PKHD1 IL17RA KRAS MCTP2 BPTF IGLL1 SCNN1A ODAD3 TK2 PSMC3IP TPM3 RNF113A MBTPS2 IGHM PDGFRB RAF1 FASLG CCDC39 MUSK FAM111B NDUFAF6 TRIP4 MS4A1 SMN1 MUSK PRKAG2 SMARCC2 HLA-DRB1 CFH LEP CYBB LMNA PSMD12 NEU1 CD3E PTPRC STAT3 PLG CHRNA1 FOXH1 TNNI3 PRKAR1A TYK2 LOX FLCN NEK9 ORC6 RNF168 PTPN11 CARD11 CD3G LONP1 TGFBR1 CC2D2A GNPTAB IDUA TREX1 CYBB NBN NRAS LPIN2 DNAAF6 TGIF1 WAC ADA FBN1 STAT3 SETBP1 ACTA1 STRA6 CD3D STAT3 ZMIZ1 ETFB RSPH4A SFTPC HLA-B TBX5 TSC1 DNMT3B A2ML1 RPL10 RPL10 MEFV TP53 ITCH BRCA2 IRF2BP2 GAS1 ASXL1 NEK10 CCDC22 SAMD9 MYH7 WNT4 DOCK3 CD247 CFI RCBTB1 UFD1 TREX1 ASAH1 INPPL1 NOTCH2 SERPINF2 MECP2 DKC1 KAT6B MEFV GLDN CHRNG HYDIN CDT1 DNAAF2 IL6R LAMB3 NFKB1 RUNX2 IL1RN GLI3 IRAK1 KANSL1 DLL3 PTCH1 TGFBR1 NDUFB10 REN TDGF1 ABCA3 RAG1 KIF11 FGFR1 UBE2A MYOD1 NFKB2 PIK3CD SMN1 FREM2 TGIF1 LAT HELLS ZEB2 RSPH9 NSDHL SERPINH1 MTHFD1 FAM13A SETD2 PAX6 SOX18 SMARCD1 OCRL SLC52A3 BMPR2 DZIP1L TDGF1 WDR1 ALB CD28 ADA2 RAPSN DLL1 RBPJ WDR19 HLA-DRB1 SHH BMPER MYLK TMEM94 SIX3 PML TGFB3 MYL2 STAG2 TBL1XR1 FBN1 EFL1 TERC BUB3 HES7 FOXC2 RBM10 CFAP410 MASP2 TRIP13 GLB1 MEG3 MYH3 LIG4 PARN RHOH NFKB2 EDARADD DNAAF6 BCR RNF125 TLL1 DCLRE1C SCNN1A GPC3 ASAH1 SNAP25 NR5A1 NHP2 DNAAF5 DLL1 EXTL3 PRPS1 MAN2B1 FANCB COMT ZMYND10 FOXN1 PRKCD BLNK NTNG1 IL2RG IL7R EMG1 TRPV4 SMPD1 ETFA IRF5 NODAL WT1 NECTIN1 LAMTOR2 RAG2 ROR2 ADA FCGR2A IER3IP1 CYTB KDM6A BTNL2 WNT3 TLL1 ALOXE3 TGIF1 ASCC1 PIGN BNC1 RIPPLY2 BAP1 NOS1 NXN DSP DNAH1 ITPR1 IGH PIEZO1 CSPP1 COL3A1 ARHGAP31 MS4A1 NODAL USB1 LRRC56 NPM1 TSC2 ATP6V0A2 DHCR7 ZBTB16 EPG5 TINF2 CASP8 PRPS1 IKBKB ARID2 SHH ARID1B RLIM EGFR CDKN2A LAMA3 SFTPA1 IKZF1 CAV1 PLOD1 PRKDC LMNA JAK3 BMP2 AKT1 CFTR ELN AGT DNAAF4 ATP6V1E1 IFT140 BTK BTNL2 COPA PEPD SCNN1B KCNJ6 GAA MCIDAS PTEN SOX4 ZMYND10 UNG GATA6 DYNC2I1 PSAT1 GATA4 SLC26A2 NDN BCOR NAB2 CD81 NKX2-1 PLOD1 PLEC FUZ CRTAP FGF8 GAS1 ABCA12 REST B3GLCT IGH CLIP2 SCNN1B H19 CYBC1 ELN RAG1 ALDH18A1 MYT1L KLHL41 ACE RSPO2 CLEC7A HIRA GP1BB DRC1 GDF1 TP53 GLI3 SVBP TCIRG1 FRAS1 IRF5 GDF1 PMM2 PAFAH1B1 ZMPSTE24 TGM1 DLL1 SIX3 CCNQ TIMM8A ELN PTEN FUCA1 MYD88 SPAG1 ARID1B AGGF1 THOC2 ABCA3 ARSB CFB PORCN HFE SOX11 NOTCH1 FOXP3 TERC USP9X P4HTM DRC1 AP3B1 CBL POLA1 CDON PKHD1 TAF1 COLQ SON TRPV3 TSC1 DVL3 TCF3 TRIP4 CHEK2 FLNB STAT5B STXBP2 CREBBP NPAP1 FAM20C STK36 DOCK8 SLC7A7 DDR2 TTC37 CD8A DOCK6 CD46 CCDC65 BCL2 INPPL1 DIS3L2 MFAP5 TNFRSF13C KNSTRN RPS15A GLA SELENON LRRC6 KMT2E SLC5A7 TERT GRIP1 DYNC2I2 PTPN22 FAT4 SHH IFIH1 IL7R PARN ARHGAP31 CSF2RB CHST14 TANC2 CIITA ZIC2 FLNA G6PC3 MARS1 BACH2 ZNHIT3 DNAJC21 SH2D1A CCNO COL13A1 DISP1 IL21 HYDIN MGP IL2RA MED25 GSN FOXH1 SLC35C1 PNP PRTN3 SP110 ARID1A MEFV NOD2 SERPINA1 NHP2 MED13 FRAS1 NBN MCIDAS FCGR2B KLHL40 BLM RAG1 RRAS TAP1 SNRPN ADGRG6 NADK2 SLC26A2 DDR2 ZAP70 MAGT1 FGFR1 GATA2 ALOX12B TMEM260 IFNGR1 SMAD4 SLC7A7 NFKB1 RB1 RARB APOE GATA6 DOCK8 AP3D1 SOS2 STING1 CASP10 B2M FLCN SRP54 ZEB2 TNFRSF13C FADD C4A TTC12 TAP2 KPTN STN1 LBR SNRPN DNAI2 MRAS COL2A1 RNF168 CHRM3 CCNO CHRNG RAC1 FGFR3 LGI4 ADA NUP88 TBX20 ODAD2 BCL10 FLNA SLC25A22 ELN SMO GBA TGFB2 NUMA1 RAG2 GATA4 DNAH9 SMARCA4 TNFRSF11A IRAK4 GUSB CD40LG SCNN1G SLC34A2 DHCR7 MIF GUSB KITLG KIAA0586 GRIP1 NSD2 DPF2 SLC35A1 EIF2AK4 GBA SPP1 NCF2 MKKS GAS2L2 MYH3 TBCD HLA-DRB1 PTPN22 RAC2 DDX6 CEP57 RELA PTCH1 DNAI2 ZFPM2 TPP2 RAG1 STAT6 IFT43 KANSL1 PURA LRRC56 DNAAF1 SCNN1G IL6ST ACP5 XIAP IL2RG FANCB IGLL1 AFF4 SCNN1B BCORL1 BTK PCNT MUC5B MRPS22 CDON COG4 PRKCD PTPN11 LRRC8A PHGDH BGN DVL3 PSAP HLA-DQA1 DYNC2I2 SLC35C1 PWAR1 SLC1A4 CR2 TBCE AGRN CTCF FBLN5 VANGL1 TRIP11 NKX2-5 TSC2 GFI1 TNFSF12 GAS8 MAPK1 SLC11A1 IFNG FBN1 DNAAF2 SCNN1A ACTA1 MESP2 HABP2 NDN SLCO2A1 FOXE3 IDS PANK2 FGFR1 CHD7 DNAAF3 NABP1 DNAAF3 CFI DPM2 OCA2 PCGF2 SFTPB MANBA TNNT2 SRP54 PLVAP CD79B SOX18 INVS DYNC2LI1 RARB CD19 FOXJ1 BMPR2 PIGN LEP PKD1L1 NHLRC1 GPC6 ITCH APC2 GATA6 SCNN1A SERPINA1 ATM GBA DNAJB13 CEP120 TNFRSF1A KIAA0319L CLCN7 NSD1 CACNA1C SPEF2 PIEZO2 DYNC2I1 NKX2-5 CREBBP TBX1 TNFSF12 COL6A2 EFEMP2 RAC2 PRSS2 TBL2 CFTR IL10 CFAP298 DONSON RSPH3 ABL1 EVC SDCCAG8 DNAH5 WIPF1 PARN PDGFRA TINF2 NCF2 TNFRSF1B CEP120 FOXP1 RFC2 NPHP3 BCOR GATA4 SNORD116-1 POLR2A NOP10 CCDC103 OFD1 DNAAF5 GATA6 IL6 POLA1 PDHA1 LMNA CD19 SFTPC SIX3 LTBP3 SMPD1 SMARCD2 RIPK4 CSF2RB PSMB8 HPS4 CRKL PTH1R EP300 RSPH1 PERP ATM ABCA3 DCTN4 CLCA4 CTSC STAT3 CCND1 POLR3H TRIP13 FCGR2A MST1 MUC5B DNAH5 CDON TRAF3IP2 IDS SRSF2 SLC18A3 TRIM28 CD79A PIK3R1 GRHL3 NOP10 HPS6 WNT3 RPGR DPP9 RAF1 SCNN1G CD79B RSPO2 BCL11B IVNS1ABP ACTL6A ZIC2 AFF4 SMAD3 ITGA7 CITED2 ERCC2 RAB3GAP2 TRIP11 IL23R SPINK1 TERC RTEL1 CYBA TSC2 CITED2 GLE1 GPC3 TGFB2 SCN9A RASGRP1 FGF8 SNRPN DYNC2I1 CARD11 POLE ICOS FADD NME8 HLA-DQB1 LMNA PGM3 EOGT CDCA7 WT1 SAMD9L SMC1A ICOS GLI3 SREBF1 CHAT RFX5 FOXF1 TDGF1 CHST14 CCDC40 SMARCE1 DCLRE1C ALMS1 TLR4 NCF1 RSPH3 CYBC1 SLC25A1 PTCH1 IL2RG B3GALT6 GLI2 GAS1 TNFRSF13B TET2 NRAS WAS ZMPSTE24 EHMT1 WRAP53 FAS WDR35 HPS1 NSMCE3 TGIF1 GLUL SH3KBP1 RFXAP CARMIL2 BCOR GTF2I TNFRSF1A MAGEL2 STAT4 HGSNAT SMAD3 FBLN5 MYO9A GTF2H5 NEK8 TERT RUNX1 RYR1 FAT4 CLPB RIPK1 COL13A1 JAGN1 CIITA TBX20 CSPP1 DNAAF4 CCR1 HK1 MINPP1 UBAC2 NFIX RNU4ATAC BIRC3 WNT4 IKBKB CD27 FAS NLRC4 SFTPA2 NDN AARS2 TGFB1 DHCR24 PIK3R1 HYLS1 CREBBP CHRND ALPL ITK VHL CCDC103 GREB1L ERAP1 FARSB RAB27A NAGLU ODAD1 CTC1 ZCCHC8 TRMT1 SNRPN CEP55 PRPS1 DLL3 LYST KEAP1 GBA JAG1 NME8 MYPN STX1A TNFRSF13C FIP1L1 HERC2 ELANE CORO1A SYT2 CCDC39 CFTR GPC4 ITGA8 ICOS RFXANK KLRC4 DNASE1 DICER1 EP300 PRKAR1A MAGEL2 MLXIPL LZTR1 PIGN BMP15 HLA-DRB1 COL2A1 ADAMTS2 WDR19 ALG12 AK2 CD55 HLA-DRB1 GAS8 DKC1 NKX2-1 DLK1 SCN10A DYNC2I2 HELLPAR LMOD3 FLCN WT1 NODAL LRBA ELANE GTF2E2 SGSH GPR35 BAZ1B SFTPB TRAPPC4 PLP1 CACNA1B RSPH4A FSHR TERT CCDC65 WT1 TERC MID1 NR2F2 DHCR24 ERCC3 WASHC5 NIPAL4 LFNG VPS33A CD19 RLIM GALNS OSTM1 XIAP ASAH1 HLA-B DISP1 NAA10

    Reports

    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  

    Interventions

    4,818 reports on interventions/drugs

    MeSH

    706 reports on MeSH terms

    HPO

    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook